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Abstract 
 
Protein kinase C (PKC) comprises a family of serine/threonine kinases which play 
central roles in intracellular signal transduction typically triggered by recruitment to 
membraneous compartments. The epsilon isoform of PKC (PKCε) has been shown to 
localize to cell-cell contacts and to the cytokinetic furrow/midbody, indicative of a role 
in the cell cycle. Both recruitment patterns can be visualized under conditions of PKCε 
inhibition, which is selectively achieved using a gatekeeper mutant (PKCε-M486A) and 
the inhibitor NaPP1.  Initial studies indicated that interphase and mitotic cells were not 
distinguished in their capacity for PKCε-M486A recruitment as evidenced by optical 
trapping experiments. I therefore assessed whether recruitment to the furrow/midbody is 
a general property reflecting the juxtaposition of two membranes and a cell-cell contact 
response.  I have successfully used fluorescence recovery after photobleaching (FRAP) 
to distinguish between the localization at the furrow/midbody from that at cell-cell 
contacts by measuring PKCε-M486A turnover at these two compartments. It is 
demonstrated that PKCε-M486A has a slower turnover at the furrow/midbody.  
The distinct kinetic behaviour of PKCε M486A at the furrow/midbody is indicative of 
other factors contributing to recruitment and/or retention. Sites and domains within 
PKCε-M486A were therefore assessed for their involvement in this process using a 
combination of mutagenesis and confocal microscopy. Through these studies I have 
identified a short motif in the regulatory domain of PKCε-M486A, the inter C1 domain 
(IC1D), that is in part required for the accumulation of PKCε-M486A at the 
furrow/midbody. The deletion of this domain (PKCε-∆IC1D-M486A) prevents the 
kinase being recruited to the furrow/midbody despite, the recruitment and 
furrow/midbody localization of the co-expressed PKCε-M486A.  
Given that the IC1D was previously identified as an actin-binding region, I have 
assessed the relationship between actin and PKCε-M486A recruitment by manipulating 
actin polymerization. Using latrunculinA, an inhibitor of F-actin assembly, I have 
shown that PKCε-M86A and RhoA colocalize and are stabilized in the same 
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compartment in conditions where F-actin is depolymerized. Importantly, the behaviour 
is observed for both active and inactive PKCε-M486A. This condition may be 
analogous to a stage in midbody biogenesis and may be evidence of the requirement of 
F-actin for normal PKCε and RhoA behaviour in cytokinesis.  
These data show some progress towards understanding the unique behaviour of PKCε at 
the furrow/midbody and indicate a complex relationship between PKCε, actin and 
RhoA.  
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Chapter 1. Introduction 
 
1.1 The Cell Cycle and Cancer 
 
Human development from a single-cell zygote to a fertile adult, consisting of 
approximately 100,000 billion cells, requires many rounds of cell division, as does the 
continued renewal of many parts of the mature adult. While the formal definition of cell 
division came in 1855 with Rudolph Virchow’s aphorism “omnis cellula e cellula” 
(every cell from a pre-existing cell) it is only during the last four decades that a 
molecular mechanism has emerged. During each division cells complete an ordered 
series of events, known collectively as the cell cycle (Figure 1.1), which consists of four 
distinct phases; a DNA synthesis (S) phase and a mitotic (M) phase separated by two 
‘gap’ phases (G1 and G2). M is further subdivided into nuclear division (mitosis) and 
cytoplasmic division (cytokinesis). It is essential that the different phases of the cell 
cycle are precisely coordinated. The phases must follow in sequential order and one 
phase must be completed before the next phase can begin. Errors in coordination are 
associated with many human diseases, in particular inappropriate proliferation has been 
identified as one of the hallmarks of cancer (Hanahan and Weinberg, 2000, Hanahan 
and Weinberg, 2011). It is therefore not surprising that the cell cycle has become an 
active area of drug discovery.  
Progression through the cell cycle is complex but tightly regulated by protein kinases in 
particular cyclin-dependent kinases (Cdks). Cdks are a family of small Ser/Thr kinases 
whose periodic activation is driven by forming bipartite complexes with different 
cyclins (reviewed in Suryadinata et al., 2010). When active, these complexes function 
by phosphorylating a multitude of downstream transducers that act on various 
components of the cell cycle apparatus. In Schizosaccharomyces pombe and 
Saccharomyces cerevisiae cell division cycles (Cdcs) are regulated by only a single 
Cdk, p34cdc2 and Cdc28 respectively, coupled with several different cyclins that are 
expressed at different cell cycle phases. Higher eukaryotes also use a variety of different 
cyclins but in contrast, possess multiple Cdks. 
Chapter 1. Introduction 
 19 
 
Figure 1-1 Progression through the mammalian cell cycle.  
(Reproduced with permission from Suryadinata et al., 2010, Bioscience Reports, 30, 
p243-55, © the Biochemical Society). The cell cycle consists of four distinct phases; 
G1, S (DNA synthesis), G2 (together known as interphase) and M (mitosis/cytokinesis). 
Different cyclin-Cdk complexes regulate the progression of cells through the different 
phases.  
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Mammalian cell culture studies have led to the simplified but dogmatically accepted 
view that cyclin D-Cdk4/6 complexes are activated and important for progression 
during G1 (Matsushime et al., 1992, Meyerson and Harlow, 1994) the transition from 
G1 to S is mediated by cyclin E-Cdk2 (Ohtsubo et al., 1995) and Cdk2 and Cdk1 in 
association with A-type cyclins are important during S and G2 respectively (Pagano et 
al., 1992). Progression through mitosis is dependent on cyclin B-Cdk1 (King et al., 
1994). In addition to the controlled oscillations in cyclin levels and phase specific 
combinatorial associations, Cdk activity is also modulated by specific inhibitors and by 
changes in the phosphorylation of the catalytic subunit.  Furthermore, cell cycle 
checkpoints are also imposed to monitor the order and quality of the cell cycle events, 
with the option to halt the cell cycle if any perturbations are encountered (Hartwell and 
Weinert, 1989). Defects in parts of the checkpoint machinery are, unsurprisingly, found 
in cancer cells. Often the consequence of such deregulation results in a reliance on the 
remaining functional DNA damage process and this can be embraced therapeutically by 
chemically targeting the intact checkpoints resulting in synthetic lethality of cancer cells 
(reviewed in Garrett and Collins, 2011). 
 
1.1.1 Basics of Cancer 
 
As previously mentioned, the human body is comprised of billions of cells precisely 
arranged and working in concert. Normal, healthy cells divide on a regular basis for 
growth, repair and replacement purposes and this division is stringently controlled. In 
cancer however, control is lost and cells start to divide aberrantly thus paving the way 
for tumour formation. More specifically, the consecutive acquisition of a number of 
biological capabilities-the hallmarks of cancer-are necessary for tumour growth and 
progression. These include: self-sufficiency in growth signals, insensitivity to growth 
suppressors, evasion of apoptosis, limitless replicative potential, induced angiogenesis 
and tissue invasion and metastasis (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011).  Importantly, genomic instability has been suggested to explain the 
means by which these six capabilities are acquired.  
Chapter 1. Introduction 
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1.1.1.1 Self-sufficiency in growth signals 
Cancer cells must induce and maintain positively acting growth stimulatory signals to 
sustain chronic proliferation and are able to do so in number of alternative ways 
including: the production of extracellular growth signals, alterations in the receptor 
molecules (for example, PDGF and PDGF-R by glioblastomas, Westermark et al, 1995) 
and the constitutive activation of intracellular signalling pathways downstream of 
receptors (such as Ras activation, reviewed in Hanahan and Weinberg).  
1.1.1.2 Insensitivity to growth suppressors 
In contrast to the positively acting growth stimulatory signals, cancer cells also have the 
ability to circumvent negatively acting growth inhibitory signals. Tumour suppressor 
genes, that normally function to limit cell growth and proliferation, are inactivated in a 
multitude of cancers. In particular, defects in the Rb pathway (see below) are observed 
in the vast majority of human cancers (reviewed in Hanahan and Weinberg, 2011).  
1.1.1.3 Evasion of apoptosis  
Programmed cell death, triggered by various stresses including DNA damage as a 
consequence of chronic proliferation, is thought to serve as a natural barrier to cancer 
progression (Adams and Cory, 2007). However cancer cells have developed multiple 
strategies to avoid apoptosis and this includes inducing the expression of antiapoptotic 
regulators or by downregulating proapoptotic factors (reviewed in Hanahan and 
Weinberg, 2011).  
1.1.1.4 Limitless replicative potential 
While most types of healthy cells limit their replication to approximately 60-70 
divisions by progressive telomere shortening, cancer cells are able to bypass this limit 
acquiring unlimited replicative potential (Blasco, 2005). They can achieve this by 
expressing telomerase, a DNA polymerase that functions by adding telomeric repeat 
segments to the ends of DNA thus opposing the telomere shortening that would 
otherwise occur.  
1.1.1.5 Induced angiogenesis  
All cells, including cancer cells, require the continued delivery of nutrients and oxygen 
for their survival. While the normal vasculature in adults is largely quiescent, in tumour 
Chapter 1. Introduction 
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progression angiogenesis is almost always turned on (Hanahan and Folkman, 1996). At 
a molecular level, vascular endothelial growth factor (VEGF) is one known stimulator 
of angiogenesis initiation and Ras activation in cancer cells can induce its upregulation 
(Baeriswyl and Christofori, 2009).   
1.1.1.6 Tissue invasion and metastasis  
The multistep process of invasion and metastasis begins with local invasion of cancer 
cells into surrounding tissues (Talmadge and Fidler, 2010). The intravasation of said 
cells into nearby blood and lymphatic vessels then aids their transfer to distant sites. 
Extravasation and the formation of micrometastases follow. It is the growth of 
micrometastatic lesions into macroscopic tumours that accounts for approximately 90% 
of cancer deaths.  
 
1.1.2 Interphase (G1, S, G2) 
 
The G1 phase of the cell cycle serves as a ‘time delay’ not only to allow for cell growth 
but also to monitor the cell’s external environment. If extracellular conditions are 
unfavourable, cells delay progress through G1 and may even enter a quiescent state, G0. 
If however, the cell receives the necessary growth signals it can pass through the 
restriction point (R, occurring between mid and late G1) and commit the cell to one 
round of division (Planas-Silva and Weinberg, 1997). At the molecular level, it is the 
cyclin D-Cdk complexes that act to integrate these extracellular signals. In early G1, the 
product of the retinoblastoma tumour suppressor gene, Rb exists in a 
hypophosphorylated state and prevents the premature entry into S phase by tightly 
binding and repressing the activity of transcription factors, such as E2F family member 
(Zhang et al., 1999, reviewed in Harbour and Dean, 2000). During G1, phosphorylation 
of Rb by cyclin D-Cdk4 and cyclin D-Cdk6 complexes, expressed in response to 
mitogenic growth signals, cancel this growth inhibitory effect and allow transcription to 
occur and cyclin E is synthesised (Harbour et al., 1999). When cyclin E is abundant and 
conditions are favourable, it interacts with Cdk2 and allows the progression from G1 to 
S phase. One of the most crucial targets of cyclin E-Cdk2 is Rb (Hinds et al., 1992), 
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which is able to completely dissociate from E2F and permit the transcription of genes 
required for S phase. As cells progress into S phase, cyclin A becomes the primary 
cyclin associated with Cdk2.  
In order for two copies of the genome to be equally distributed to the daughter cells at 
M phase, DNA must be precisely replicated in the parental cell during S phase. DNA 
replication begins with the assembly of the pre-replication complex (pre-RC) during G1 
(reviewed in Woo and Poon, 2003). Briefly, this complex consists of the origin 
recognition complex (ORC), Cdc6, chromosome licensing and DNA replication factor 
(Cdt1) and the mini-chromosome maintenance 2-7 (Mcm 2-7) (Santocanale and Diffley, 
1996, Aparicio et al., 1997, Tanaka et al., 1997, Nishitani et al., 2000). Once the DNA 
is ‘licensed’ to replicate, pre-RCs are phosphorylated by cyclin-Cdk complexes, which 
in turn triggers the appropriate modifications required for replication initiation, 
including loading of DNA polymerases. Interestingly, cyclin A-Cdk2 appears to 
mediate elongation (Bashir et al., 2000) and phosphorylates several components of the 
replication machinery, including DNA polα (Nasheurer et al., 1991), DNA pol δ (Zeng 
et al., 1994) and proliferating cell nuclear antigen (PCNA, Prosperi et al., 1994). 
Furthermore, cyclin A-Cdk2 is also required to prevent re-replication as it 
phosphorylates Cdc6, sequestering the protein from the nucleus to the cytoplasm 
(Petersen et al., 1999). The resultant sister chromatids, are then physically linked as a 
results of cohesion loading by the cohesion complex (Uhlmann et al., 1999).  
At the end of the S phase, A-type cyclins associate with Cdk1 and participate in the 
progression of G2. Much of G2 is spent growing into the size that is required for M 
phase. The activation of cyclinB-Cdk1 then allows entry of the cell into mitosis by 
promoting the phosphorylation of components which are involved in, for example, 
chromosome condensation, disassembly of the nuclear lamina and breakdown of the 
nuclear envelope (Nigg, 1995). 
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1.1.3 Mitosis 
 
Prior to cytokinesis, mitosis is required to precisely regulate the segregation of 
replicated DNA so that when the two daughter cells are formed they will each inherit an 
identical set of chromosomes (reviewed in Walczak et al., 2010). The process of mitosis 
can be divided into distinct phases: prophase, pro-metaphase, metaphase, anaphase and 
telophase (Figure 1.2). First, during prophase, the chromosomes condense inside the 
nucleus and microtubule nucleation at centrosomes increases. Pro-metaphase follows 
and is marked by nuclear envelope breakdown and attachment of the kinetochores 
(specialised protein complexes that assemble on centromeric DNA) of individual sister 
chromatids to microtubles originating from the opposite poles. During this stage the 
spindle assembly checkpoint (SAC) operates to ensure correct chromosome alignment 
and biorientation on the mitotic spindle by sensing microtubule attachment and gain of 
spindle tension (Rieder et al., 1994, Li and Nicklas, 1995). By the action of the SAC 
proteins (including Mad2, Bub1 and BubR1, Chen et al., 1996, Li and Benezra, 1996, 
Taylor and McKeon, 1997, Skoufias et al., 2001) the function of Cdc20 is inhibited 
(Yu, 2007) and cyclin B is stabilized until all chromosomes are correctly attached to the 
mitotic spindle at metaphase. On achieving the latter, the anaphase-promoting complex 
(APC/C), a multisubunit E3 ubiquitin ligase, becomes activated by binding Cdc20 and 
marks cell cycle proteins, including cyclin B and securin, for degradation (reviewed in 
Pines, 2006, Holloway et al., 1993, Yu, 2007). Destruction of these mitotic regulators 
lead to the inactivation of Cdk1 and the cohesin complex (more specifically its subunit, 
scc1, Uhlmann et al., 1999) Scc1 cleavage destroys the link between sister chromatids 
and thereby promotes anaphase.  Once each set of sister chromatids have reached the 
opposite spindle poles, the chromosomes decondense as the nuclear envelope reforms 
around the two daughter nuclei (telophase). Ingression of a cytokinetic cleavage furrow 
between the segregated chromosomes then partitions the remaining cellular material and 
is discussed in more detail below.  
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Figure 1-2 Progression through mitosis and re-entry into interphase.  
(Reprinted with permission from Macmillan Publishers Ltd, Nature Reviews Molecular 
Cell Biology Walczak et al., 2010, 11, p91-102). Mitosis is subdivided into prophase, 
pro-metaphase, metaphase, anaphase and telophase, see text for details.  
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1.2 Cytokinesis 
 
The final bifurcation of a ‘pre-existing’ cell, cytokinesis, is the concluding step in cell 
division. The process begins at anaphase onset when the mitotic spindle undergoes 
complex structural changes including the growth of astral microtubules towards the cell 
cortex and central spindle formation inbetween the segregating chromosomes. These 
anaphase spindle structures induce localized activation of the small GTPase RhoA 
(reviewed in Douglas and Mishima, 2010) which in turn triggers the formation of a 
contractile ring, a network of actin and myosin filaments. Contraction of the actomyosin 
ring forms a cleavage furrow typically around the middle of the cell and ingresses until 
the dividing cells are connected by a narrow, tubular intracellular bridge, containing the 
midbody. Dissolution of the bridge completes cytokinesis and two daughter cells are 
formed (reviewed in (Glotzer, 2005, Eggert et al., 2006, Barr and Gruneberg, 2007). 
Although less well understood than some of the earlier phases, it is by no means less 
critical and failure to complete cytokinesis can lead to genetically unstable tetraploid 
cells (Fujiwara et al., 2005), a prelude to aneuploidy, the most common characteristic of 
human solid tumours (reviewed in Kops et al., 2005). In order to be able to assess 
whether intervention might bring benefits in the treatment of cancer, a detailed 
understanding of the mechanisms involved are required.  
 
1.2.1 Selecting the site of cell division  
 
One of the first steps in cytokinesis is determining the site of cell division, ensuring that 
it is correctly positioned between separating chromosomes so that each daughter cell 
receives only one copy of the genome. For over forty years the mitotic spindle has been 
consistently associated with defining this position, however there has been much debate 
regarding the exact part of the spindle apparatus which is responsible. Classic 
experiments performed on marine invertebrate eggs established the importance of 
spindle asters (Rappaport, 1961) whereas in comparatively more recent studies, the 
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signalling potential has been reported to occur via the central spindle (Giansanti et al., 
1998). Consequently, different models have been proposed to explain the induction of 
furrow positioning (see Figure 1.3 and corresponding figure legend for a detailed 
explanation). It has been suggested that all organisms have the potential to use both the 
aster-directed and central spindle pathway to initiate and execute cleavage furrow 
formation but the relative importance between the two differs between cell types and 
species (reviewed in Barr and Gruneberg, 2007). Although the molecular details of the 
aster-directed pathway are beginning to emerge, there is a much clearer understanding 
of those components involved in the central spindle pathway.  
 
1.2.2 Central spindle assembly 
 
The proteolytic degradation of cyclin B, as a consequence of APC activation following 
the satisfaction of the SAC (Holloway et al., 1993) inactivates Cdk1 and permits 
dephosphorylation and subsequent activation of proteins that are critical for the 
assembly of the central spindle. Factors that contribute to the central spindle assembly 
include; Prc1, a microtubule-associated protein with microtubule bundling activity 
(Mollinari et al., 2002) and the centralspindlin complex composed of the kinesin motor 
protein MKLP1 and the Rho-family GTPase activating protein (RhoGAP) MgcRacGAP 
(Mishima et al., 2002).  Cdk1 phosphorylation sites have been mapped in both Prc1 and 
MKLP1 and consistent with their recruitment negatively regulated by Cdk1-cyclinB 
mediated phosphorylation, Ala substitutions of a subset of these sites cause the 
premature association of both to the central spindle (Mollinari et al., 2002, Mishima et 
al., 2004).   
The stable localization of centralspindlin also depends on the chromosomal passenger 
complex (CPC) which includes the kinase aurora B and its coactivator the inner 
centromere protein, INCENP (Kaitna et al., 2000). Both MgcRacGAP and MKLP 
contain phosphorylation sites for aurora B. Whereas the phosphorylation of the N-
terminal of MgcRacGAP has been proposed to affect binding to Prc1 (Ban et al., 2004), 
phosphorylation of the GAP domain has been reported to convert MgcRacGAP  
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Figure 1-3 Three schematic models for the positioning of cleavage furrow. 
(Reproduced with permission from ©2004 Rockefeller University Press. Originally 
published in J.Cell Biol. 164:347-351). A) Astral stimulation model. According to this 
model, astral microtubules provide a cleavage furrow stimulus which is transported 
along astral microtubules. Given that microtubules from both poles project towards the 
equatorial cortex, it is assumed that the strength of the stimulus is maximal here. B) In 
contrast to A) the astral relaxation model assumes that the density of astral rays, is 
greater at the poles compared with at the equator causing these regions to be less 
contractile and consequently inducing equatorial furrowing. C) In the central spindle 
model, the overlapping microtubules between segregating chromosomes, provides a 
platform for which to recruit key regulators of RhoA. In turn they are able to function 
by signalling to the overlapping equatorial cortex.  
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into a RhoGAP (Minoshima et al., 2003). Aurora B mediated phosphorylation of 
MKLP1 further serves to assemble the central spindle by preventing 14.3.3 mediated 
sequestration of MKLP1 in the cytoplasm, instead promoting its association with aurora 
B at the central spindle (Douglas and Mishima, 2010). 
 
1.2.3 Actomyosin contractile ring assembly 
 
Once assembled the central spindle serves as a platform for the coordinated recruitment 
of numerous signalling proteins that regulate RhoA at the equatorial cortex and promote 
furrow ingression. RhoA is a central player in contractile ring assembly, which is 
attached to the plasma membrane to create a cleavage furrow that partitions the cell into 
two (reviewed in Glotzer, 2005). Like many of its fellow small GTPases, RhoA 
switches between an active GTP-bound form and an inactive GDP-form. The cycling of 
RhoA between these two states is regulated by guanine nucleotide-exchange factors 
(GEFs) and GTPase activating proteins (GAPs). GEFs activate RhoA by promoting the 
release of GDP and the consequent binding of GTP (which is present in an ~10-fold 
excess over GDP), whilst GAPs inactivate RhoA by increasing the intrinsic GTPase 
activity. Only in its active, GTP-bound state is RhoA able to interact with and activate 
downstream effector proteins (reviewed in Heasman and Ridley, 2008). However the 
precise mechanisms of RhoA localization at the equatorial cortex and its activation 
remain unclear. Interestingly, astral microtubules have been shown to be essential for 
localising RhoA and inducing contractile ring formation at the equatorial cortex in 
NRK-52E cells (Nishimura and Yonemura, 2006). In contrast, central spindle 
microtubules were shown only to recruit RhoA to the cortex when the central spindle 
microtubules were in close enough proximity (Nishimura and Yonemura, 2006).  
The RhoA GEF Ect2 is a critical RhoGEF in cytokinesis. Overexpression of Ect2 
lacking its GEF domain inhibits the completion of cytokinesis in mammalian cells 
(Tatsumoto et al., 1999) and depletion of the entire Ect2 prevents cytokinesis in human 
cells (Kim et al., 2005). Ect2 localizes to and becomes active at the central spindle by 
binding to MgcRacGAP. More specifically, through its association with Prc1, 
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mammalian Polo-like kinase (Plk1) is recruited to the central spindle where it functions 
to phosphorylate the N terminus of MgcRacGAP, generating a phospho-epitope 
recognised by the BRCA1 C-terminal (BRCT) domain of Ect2 (Petronczki et al., 2007, 
Wolfe et al., 2009). Complex formation between MgcRacGAP and Ect2 is thought to 
relieve Ect2 autoinhibition which then signals to the overlying equatorial cortex by 
activating a local pool of RhoA (Yuce et al., 2005). In contrast, Nishimura and 
Yoemura have proposed a model whereby localization of the centralspindlin complex to 
the tips of the astral microtubules localize Ect2 to the equatorial cortex and results in 
active RhoA accumulating there. They suggest that the role of the centralspindlin-Ect2 
complex at the central spindle is merely to maintain active RhoA during furrow 
ingression. Interestingly, Ect2 has also been shown to localize to the cortex through a 
mechanism that depends on its C-terminal pleckstrin homology (PH) domain binding 
phosphatidylinositol lipids PI(4,5)P2 (Chalamalasetty et al., 2006). Nonetheless, once 
active RhoA then acts on downstream effectors including Rho kinase (ROCK), citron 
kinase and mammalian homolog of Drosophila diaphanous (mDia) that in combination 
lead to myosin II activation and actin polymerization (Madaule et al., 1998, Kosako et 
al., 2000, Watanabe et al., 2008). 
 
1.2.4 Furrow ingression and midbody formation 
 
Once the filaments are assembled into contractile bundles around the equator, the 
progressive sliding of anti-parallel actin filaments along myosin II, in a manner similar 
to the contraction of the sarcomere, causes the bundles to shorten. This tightening 
‘purse string’ in turn is believed to provide the contractile force necessary to drive 
furrow ingression (reviewed in Wang, 2005). While this contractile ring hypothesis 
dominates current thinking, the exact mechanism of force generation remains widely 
debated. Alternative theories of force generation include the involvement of a 
subcortical cytoskeleton and spindle axis forces ‘pulling’ daughter cells away from one 
another.  
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The RhoA activated furrow continues to ingress until the dividing cell remains 
connected by an intracellular bridge (Figure 1.4). The intracellular bridge contains 
dense bundles of antiparallel microtubules and the region where they overlap is now 
referred to as the midbody. Most of the central spindle components and RhoA 
specifically localize here, collectively serving as a platform for the recruitment of 
factors essential for the completion of cytokinesis. For example, the sequential binding 
of MgcRacGAP to Ect2 and Rab11-FIP3/Eferin/arfophillin (FIP3) regulates the 
targeting of recycling endosomes to the midbody (Simon et al., 2008), which has been 
shown previously to be required for abscission (Wilson et al., 2005). Interestingly, 
evidence has also emerged in support of a role for membrane traffic at the furrow stage. 
Specifically, vesicles from the trans-golgi network (TGN) have been found to mediate 
furrow ingression (Hill et al., 2000). However, the exact role of vesicles in cytokinesis 
is yet to be resolved. In principle, vesicle fusion with the plasma membrane might act to 
trigger plasma membrane fission by suddenly increasing the membrane surface at the 
abscission site. However, the gradual reduction in TGN vesicles during furrow 
ingression perhaps suggests a more preparatory role rather than directly promoting 
abscission.   
 
1.2.5 Abscission  
 
Following its rapid assembly, the intracellular bridge can persist for up to several hours, 
ensuring the complete clearance of chromatin from the cleavage plane (Steigemann and 
Gerlich, 2009a), after which the cell finally undergoes abscission, the process that leads  
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Figure 1-4 Progression through cytokinesis.  
(Reprinted from Seminars in Cell and Developmental Biology, 21, Guizetti and Gerlich, 
Cytokinetic abscission in animal cells, p909-916, 2010, with permission from Elsevier). 
In early anaphase the components of the contractile ring have assembled. Contraction of 
the actomyosin ring is thought to provide the necessary force for furrow ingression. 
Once fully ingressed, in late cytokinesis, compression of the central spindle creates an 
intracellular bridge containing the midbody.  
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to its irreversible severing (reviewed in Guizetti and Gerlich, 2010, Steigemann and 
Gerlich, 2009b). Currently, both the regulation and mechanism of abscission are poorly 
defined. With regards to its regulation, animal cells are thought in part to be dependent 
on aurora B (Steigemann et al., 2009). It is thought that aurora B is part of an undefined 
sensor that responds to unsegregated chromatin at the cleavage site by delaying 
abscission. Maintenance of aurora B in an active state is sufficient to induce its 
relocalization to a narrow-ring at the intercellular canal where it functions to stabilize 
the structure and delay abscission. Subsequent dephosphorylation then correlates with 
abscission.  In terms of mechanics, the evidence indicates asymmetric midbody 
disassembly coinciding with either i) mechanical rupture and subsequent would healing; 
ii) targeted vesicle secretion and subsequent fusion or iii) plasma membrane ingression 
and subsequent fission (see Figure 1.5 and the corresponding figure legend for a more 
detailed explanation). 
It has been proposed that the removal of actin is also a prerequisite for this terminal step 
and could be controlled by the inactivation of RhoA. This loss of RhoA-GTP may be 
driven by control of a RhoGEF, a RhoGAP, a physical relocation of either of these 
regulators or of RhoA itself. Interestingly, recent work has uncovered the epsilon (ε) 
isoform of the protein kinase C family (PKC) acting as a key regulator at this end stage 
of cytokinesis to trigger RhoA inactivation (Saurin et al., 2008). How this particular 
control is exerted will be addressed throughout this thesis. 
 
1.2.6 Cytokinesis Failure  
 
Given that cytokinesis is such a highly ordered process it is not surprising that it can 
sometimes fail. Cytokinesis failure leads to both centrosome amplification and 
production of tetraploid cells (reviewed in Storchova and Pellman, 2004). These 4N 
cells can then undergo chaotic mitosis causing extensive genomic instability, leading 
the way to aneuploidy and ultimately tumour growth. Endoscopic biopsies of patients 
with Barrett’s oesophagus have, arguably, provided the most direct evidence for the  
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Figure 1-5 Schematic models for the process of abscission  
(Reprinted from Trends in Cell Biology, 19, Steigemann and Gerlich, Cytokinetic 
abscission: cellular dynamics at the midbody, p606-616,  2009, with permission from 
Elsevier) (a,b) Following destabilisation of the intercellular bridge, it is suggested that 
the frictional force of sister cells could induce rupturing. The holes made would then be 
filled using a process similar to that of wound healing. (c,d) Targeted secretion and 
membrane fusion model. TGN or endosome derived vesicles have been suggested to 
accumulate close to the midbody. Vesicle fuse with one another and the plasma 
membrane to support the splitting of cells. (e,f) Plasma membrane ingression for fission 
model. An alternative model proposes that disassembly of the intercellular bridge 
permits the direct fission of ingression plasma membranes.  
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tetraploid hypothesis for carcinogenesis. The progressive analysis of these patients has 
revealed a striking correlation between the early loss of p53 (a gene required for the 
tetraploid checkpoint), the acquisition of a population of tetraploid cells and the 
development of aneuploidy (Reid et al., 1996, Margolis et al,. 2003). However, given 
the genetic complexity of aneuploid cells, it still remains widely debated as to whether 
aneuploidy is a causative effect or merely a consequence of transformation. It is 
therefore important to conclusively prove whether a tetraploid intermediate, occurring 
as a result of cytokinetic failure, has a role in genomic instability in tumours. 
 
1.3 Protein Kinases 
 
Mammalian protein kinases are key regulators of almost every aspect of eukaryotic 
cellular behaviour, including cell cycle progression, metabolism, apoptosis and 
differentiation. They constitute one of the largest and most functionally diverse gene 
families and catalyse the rapid and reversible transfer of γ-phosphate from adenosine 
triphosphate (ATP) to protein hydroxyl groups on Ser, Thr and Tyr residues (Hanks and 
Hunter, 1995, Manning et al., 2002).  
 
1.3.1 AGC kinases  
 
PKC belongs to the AGC superfamily of Ser/Thr protein kinases and based on the 
sequence alignment of its kinase domain was one of the three defining subfamilies, 
along with cAMP-dependent protein kinase 1 (PKA) and cGMP-dependent protein 
kinase (PKG). It is now held in wide regard that the AGC family contains sixty out of 
the five hundred and eighteen human protein kinases identified by the human genome 
project (reviewed in Pearce et al., 2010). Currently, fourteen AGC kinase domain 
structures have been solved, all of which exemplify the prototypical bilobal kinase fold 
initially described for PKA (Knighton et al., 1991). In the bilobal kinase fold, an amino-
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terminal small lobe (N-lobe) and a carboxyl-terminal large lobe (C-lobe) surround one 
molecule of ATP and a deep cleft, between the two, forms an active site. While the N-
lobe is associated with nucleotide binding, the C-lobe is primarily involved in substrate 
binding and catalysis. The αC helix, located in the N-lobe and a C-terminal tail are also 
critical for regulatory interactions between the two.  
In addition to the high degree of primary sequence conservation within the kinase 
domain, AGC protein kinases share a conserved system for regulating the intrinsic 
activity of these domains. Generally, this involves phosphorylation at three conserved 
priming sites; the activation loop (found in the C-lobe), the hydrophobic motif and the 
turn motif (both located in the C-terminal tail). 
While phosphorylation of the activation loop typically involves phosphoinositide-
dependent kinase 1 (PDK1, Alessi et al., 1997), accumulating data indicate that the 
mammalian target of rapamycin (mTOR) mediate the phosphorylation of the 
hydrophobic motif and turn motif of several AGC kinases (reviewed in Jacinto and 
Lorberg, 2008). There are two distinct mTOR protein complexes, mTORC1 and 
mTORC2, differing in their molecular composition and sensitivity to rapamycin. In 
mTORC1, mTOR forms a complex with regulatory associated protein of mTOR 
(Raptor) and mammalian lethal with sec thirteen (mLST8) and mediates the rapamycin 
sensitive function of mTOR (Kim et al., 2002). In contrast, mTORC2 signalling is 
rapamycin insensitive and mTOR forms a complex with rapamyicin-insensitive 
companion of mTOR (Rictor), stress-activated protein kinase interacting protein 1 
(Sin1) and mLST8 (Pearce et al., 2007, Yang et al., 2006).  
Apart, from the kinase domain the AGC kinases show little similarity and not 
surprisingly are activated downstream of a wide range of extracellular stimuli by 
distinct mechanisms. For example, PKB, p70 ribosomal S6 kinase (S6K) and serum and 
glucocorticoid induced protein kinase (SGK) are downstream mediators of 
phosphoinositide 3-kinase (PI3K, Ming et al., 1994, Franke et al., 1995, Kobayashi and 
Cohen, 1999). PKA is subject to control by cAMP (Taylor and Young, 1990) and p90 
ribosomal kinase (RSK) and mitogen and stress activated protein kinase (MSK) are 
effectors of extracellular signal-regulated kinase (ERK) and ERK/p38 mitogen-
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activated protein kinases (p38 MAPK) respectively (Dalby et al., 1998, Deak et al., 
1998). In the case of PKC, the subject of this thesis, activation is generally downstream 
of phospholipase C (PLC).  
 
1.3.2 Protein Kinase C   
 
PKCs contribute a significant number of members to the AGC superfamily and 
currently, nine PKC isoforms have been identified unequivocally (reviewed in Mellor 
and Parker, 1998, Steinberg, 2008). In addition to the highly conserved carboxyl-
terminal catalytic kinase domain, PKCs contain an amino-terminal regulatory domain. 
Both structures are composed of a number of conserved regions (C1-C4) interspersed 
by regions of lower homology, termed variable domains (V0-V5). Structural differences 
within the regulatory domain confer variations in cofactor requirement and 
consequently subdivide the family into three groups (Figure 1.6). The best characterized 
and first discovered are the conventional PKCs (cPKC): α, the βI/βII splice variants and 
γ subtypes, which are all DAG and Ca2+ dependent; in this case a duplicated Cys-rich 
motif (the C1 domain) binds DAG, while the C2 domain contains a Ca2+ binding site. 
The second best characterized PKCs are the novel PKCs (nPKC): δ, ε, η and θ 
subtypes. These isoforms are structurally similar to the cPKCs, except that the C2 
domain does not contain the functional Asp residues that appear to mediate Ca2+ 
binding, nPKCs are therefore classified as Ca2+ independent but DAG dependent. The 
least understood isoforms are the atypical PKCs (aPKC): ζ and λ/ι subtypes. They 
contain a variant of the C1 domain with an impaired ligand-binding pocket that does not 
bind DAG and the C2 domain is replaced by a Phox/Bem1 (PB1; protein interaction 
domain). Consequently, aPKCs are DAG and Ca2+ independent and regulation occurs in 
part through the N-terminal Phox/Bem1 (PB1) domain and protein interactions.  
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Figure 1-6 PKC structure and classification 
(Reprinted with permission from Macmillan Publishers Ltd, Nature Reviews Cancer, 
Mackay and Twelves, 7, 554-562, 2007). PKC has four conserved domains (C1-C4) 
located within two regions (regulatory and catalytic). Schematic includes the 
pseudosubstrate (burgundy rectangle), C1 domain and C1-like (green rectangle), C2 
domain and PB1 (blue rectangle), the connecting variable regions and kinase domain 
(red and cream rectangles). The 3 priming phosphorylations for PKCβII, PKCε and 
PKCζ are shown also.  
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1.3.3 Protein Kinase C and Cancer 
 
PKCs have been linked to cancer progression ever since the 1980s when it was 
discovered that tumour promoting phorbol esters were PKC activators in 2 stage 
carcinogenesis models (Castagna et al., 1982, Kikkawa et al., 1983, Leach et al., 1983). 
Extensive research since has indeed established key roles for PKC isoforms in 
malignant transformation. Although mutations and chromosomal rearrangements are 
rare, alterations in the expression of PKC in human cancers are regularly displayed 
(Table 1.1), the profile of which is dependent upon the particular cancer type (reviewed 
in Griner and Kazanietz, 2007). Currently, little is known as to whether changes in PKC 
expression are a consequence of genetic and/or epigenetic effects.  
 
1.3.4 PKC regulation-priming site phosphorylation 
 
In common with other members of the AGC kinase superfamily, PKC activity typically 
requires phosphorylation at three conserved priming sites (two for ζ and λ/ι); the 
activation loop, the hydrophobic motif and the turn motif (in aPKCs a phosphomimetic 
is present at the hydrophobic motif). In the absence of phosphorylation at one or more 
of these sites, catalytic activation is impaired or enzyme stability is compromised 
(reviewed in Newton, 2009, Freeley et al., 2011).  
Phosphorylation of the activation loop in most PKC isoforms is critical for catalysis. 
Moreover, it likely represents the first phosphorylation event in the processing series, as 
substitution of the activation loop Thr of cPKCs with a neutral or non-phosphorylable 
residue abolishes activity and prevents the subsequent phosphorylations on the C-  
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PKC isoform Tumour type Expression  Correlation 
α Bladder Increased With tumour grade 
 Brain Decrease Level of cellular differentiation 
 Brain Increased  With tumour grade 
 Breast Decreased With tumour grade 
 Ovarian Decreased  With tumour grade 
 Renal Decreased ND 
 Colon Decreased ND 
 T- cell leukaemia Decreased  ND 
β Bladder Decreased With tumour grade 
 Colon Decreased ND 
 Prostate Decreased Implicated in early stage tumour 
development 
 T-cell leukaemia Decreased ND 
 Melanoma Decreased ND 
δ Bladder Decreased With tumour grade 
 Brain  Decreased With tumour grade 
 Colon  Increased ND 
 SCC Decreased  ND 
ε Bladder Increased With tumour grade 
 Brain Increased With tumour grade 
 Breast Increased With tumour grade, poor survival, 
negative correlation with ER status 
 Colon Decreased ND 
 Prostate Increased Implicated in early stage tumour 
development 
 Thyroid Decreased ND 
η Breast Decreased With tumour grade; expression of 
MDR genes 
 Colon Decreased  Level of cellular differentiation 
 Renal Increased With tumour grade 
θ GIST Increased Diagnostic marker of tumour type 
 
Table 1-1 Expression of PKC isoforms in human tumours 
(Reprinted by permission from Macmilan Publishers Ltd: Nat Rev Cancer, Griner and 
Kazanietz, 7, 281-294, 2007). ND, not determined; ER, oestrogen receptor; GIST, 
gastrointestinal stromal tumour; MDR, multidrug resistance 
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terminal tail sites (Cazaubon et al., 1994, Orr and Newton, 1994). The molecular detail 
of this regulation has been provided by the publication of PKC kinase domain crystal 
structures including the cPKC PKCβII (Grodsky et al., 2006). The activation loop is 
located in the C-lobe and lies adjacent to the nucleotide binding site when arranged in 
the bilobal fold. It is connected to the N-lobe through the αC helix and its 
phosphorylation leads to a conformational change which coordinates the formation of a 
hydrogen bond network that is required for catalytic activity. It is now appreciated that 
activation loop phosphorylation is mediated by PDK1 and in cells that are deficient in 
PDK1, PKC levels and/or activation loop phosphorylation are significantly reduced 
(Balendran et al., 2000). Both the hydrophobic motif and turn motif are located outside 
of the kinase domain and instead they are found on the C-terminal tail. While the turn 
motif is conserved in all PKC isoforms, the hydrophobic motif is only found in cPKCs 
and nPKCs (the aPKCs instead have an acidic residue present). Structural and modeling 
studies on the kinase domains have demonstrated that the phosphorylated turn motif 
serves to stabilize the kinase core by assisting the C-terminal tail in finding its way 
around the N-lobe and helping to position the αC helix in an active conformation. 
However, there are discrepancies between the data as to the importance of this site for 
catalytic activity, whereas phosphorylation is required for PKCβI and PKCβII activity 
(Zhang et al., 1994, Edwards et al., 1999) it is found to be dispensable for PKCα, PKCθ 
and PKCι (Bornancin and Parker, 1996, Liu et al., 2002, Hauge et al., 2007). Whilst the 
turn motif site of PKCβII was initially described as an autophosphorylation site (Behn-
Krappa and Newton, 1999), recent studies have demonstrated that autophosphorylation 
is not necessarily required (Cameron et al., 2011). Rather, a subset of PKC isoforms 
have been identified as downstream targets of mTOR. Specifically, mTORC2 has been 
implicated in turn motif phosphorylation of cPKCs and PKCε. However whether 
mTORC2 controls the phosphorylation of this site either directly or indirectly is 
unclear. More importantly perhaps is that in murine embryonic fibroblasts (MEFs) 
lacking critical components of mTORC2, the levels of cPKCs and PKCε are vastly 
reduced (Ikenoue et al., 2008). 
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mTORC2 has also been implicated in the hydrophobic motif of some cPKCs and 
nPKCs. Interestingly, in human embryonic kidney cells (HEK 293), PKCε at the 
hydrophobic motif is sensitive to rapamycin (Ziegler et al., 1999), which is indicative of 
an involvement of mTORC1 rather than mTORC2 in phosphorylation. Similar to the 
turn motif, the effects of this site on catalytic activity are inconsistent but are very much 
supportive of a role in stabilizing the enzyme. From structural studies, it is 
demonstrated that phosphorylation of the hydrophobic motif is required for an 
interaction between the C-terminal tail with the hydrophobic pocket in the N-lobe, 
formed in part by the αC helix. Like the turn motif, the hydrophobic motif helps 
position the αC helix in an active conformation.  
Collectively, theses results have led to a model (Figure 1.7) in which: 1) 
unphosphorylated PKCs are in a catalytically-incompetent open conformation, probably 
constitutively on the membrane; 2) PDK1 phosphorylates the activation loop at the 
membrane; 3) PDK1 dissociates from PKC, allowing phosphorylation at the turn motif 
and hydrophobic motif by mTORC1/mTORC2 dependent pathways; 4) PKC adopts an 
activity-competent but autoinhibited conformation, once dissociated from the 
membrane. The enzyme is now in a closed configuration but access to the active site is 
sterically hindered through the binding of the pseudosubstrate sequence. The 
pseudosubstrate sequence is composed of highly conserved residues and found 
juxtaposed to the N-terminus of the C1 domain of all PKC isoforms (House and Kemp, 
1987). Activation of PKC is accompanied by its removal from occupation of the 
substrate site and is mediated by the recruitment to cell membranes or binding of 
accessory proteins.  
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Figure 1-7 A schematic outlining the cycle of generic c/n PKC activation           
(This figure was originally published in Biochemical Society Transactions, Cameron, 
Occupational hazards: allosteric regulation of protein kinases through the nucleotide-
binding pocket, 2011, 39, 472-6, © the Biochemical Society). See text for details.  
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1.3.5 PKC activation-recruitment to cell membranes 
 
DAG is produced acutely in response to phosphoinositide-specific phospholipase C (PI-
PLC) hydrolysis of PIP2 and functions to reversibly recruit cPKCs and nPKCs to the 
membrane via their C1 domains (reviewed in Newton, 2009). Specifically, the 
duplicated Cys-rich regions (HX12CX2CXnCX2CX4HX2CX7C) denoted C1A and 
C1B, are the binding sites for both DAG and the tumour-promoting phorbol esters such 
as phorbol-12-myristate-13-acetate (PMA, Castagna et al., 1982). Membrane 
phosphatidylserine (PS) also plays a critical role in this interaction and its binding is 
facilitated by a ring of positive charges around the middle of the domain. This particular 
electrostatic interaction positions the C1 domain to penetrate the membrane bilayer and 
bind the more deeply located DAG/PMA. Whereas, nearly all C1 domains have been 
shown to bind PS with equal affinity, their interaction with DAG/PMA varies. The C1 
domain of nPKCs has an affinity for DAG two orders of magnitude higher than that of 
the C1 domain of cPKCs (Giorgione et al., 2006). Recently, this has been attributed to a 
single residue in the C1B domain. A Trp residue in the lipid-binding surface of nPKCs 
is replaced by a Tyr at an equivalent position in cPKCs and appears to bind DAG-
containing membranes with lower affinity (Dries et al., 2007). Consequently, cPKCs 
must be pre-targeted to membranes by their C2 domains, in response to an increase in 
intracellular Ca2+, where they bind anionic phospholipids, with selectivity for PIP2. 
Detailed structural studies have revealed that the C2 domain assumes a compact β 
sandwich fold with flexible loops on the top and bottom. Functional Asp residues, 
responsible for Ca2+ binding, are located in the flexible top loops and bind two-three 
Ca2+ ions and also interacts with PS (Ochoa et al., 2002). A Lys-rich cluster located in 
the β3 and β4 sheets is suggested to specifically bind PIP2 (Corbalan-Garcia et al., 
2003). Once engaged on the membrane, the C1 domain can then bind PS and DAG as 
previously described. The binding of the C1 domain, or the coordinated binding of the 
C1 and C2 domains, to membranes provides the energy to release the autoinhibitory 
pseudosubstrate from the active site and thus allows efficient substrate phosphorylation.  
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1.3.6 PKC activation-binding accessory proteins  
 
The removal of the pseudosubstrate sequence from the active site in aPKCs is 
allosterically regulated by the binding of proteins. Despite the molecular detail of this 
regulation remaining unclear, a wealth of genetic data has been reported in which 
components involved have been identified (Rosse et al., 2010). One such protein-
mediated pathway involves partition defective 6 (Par6, one of the evolutionarily 
conserved polarity proteins first identified in Caenorhabditis elegans). Par6 has been 
found to associate with the N-terminal PB1 domain in aPKCs, forming a stable 
heterodimer which is then activated by members of the Rho family GTPases, Rac1 and 
Cdc42 (Suzuki et al., 2003). Consistent with the latter, Yamanaka et al showed that 
kinase activity of aPKC in the Par6 complex is enhanced by the addition of recombinant 
Cdc42 preloaded with GTP (Yamanaka et al., 2001).   
 
1.3.7 PKC degradation 
 
cPKCs and nPKCs reversibly translocate on and off membranes in response to second 
messengers and are constitutively phosphorylated. However, prolonged activation, as is 
the case with phorbol esters, results in the dephosphorylation and subsequent 
degradation of PKC (reviewed in Newton, 2009). More specifically, it has been 
proposed that the PH domain leucine-rich repeat protein phosphatase (PHLPP) 
selectively dephosphorylates the hydrophobic motif at the membrane and then shunts 
PKC to the detergent-insoluble fraction of the cell for subsequent desphosphorylation at 
the remaining sites (Gao et al., 2008). The dephosphorylated species then undergoes 
ubiquitination and proteolytic degradation by the 26 S proteasome, a large multicatalyic 
protease complex (Lee et al., 1996). Dephosphorylation, however, is not necessarily a 
prerequisite for degradation, a second pathway can coexist in which phosphorylated 
PKC is also ubiquinated and degraded (Leontieva and Black 2004). Interestingly, recent 
studies have added a layer of complexity with regards to the 
phosphorylated/dephosphorylated balance of PKC levels within the cell. Occupation of 
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the ATP binding site with inhibitors results in an increase in phosphorylation of a 
kinase-inactive ATP binding mutant (that is not normally phosphorylated) and protects 
PKCs from dephosphorylation (Cameron et al., 2009, Gould et al., 2011). 
 
1.4 PKCε in Cytokinesis 
 
1.4.1 Specific functioning of PKC isoforms 
 
PKC isoforms are widely distributed in mammalian tissues and while some are tissue 
specific (PKCγ is restricted mainly to the central nervous system and spinal cord, PKCθ 
is present in skeletal muscle and hematopoietic cells and PKCβ is found in pancreatic 
islet cells, monocytes, brain and vascular tissue, reviewed in (Way et al., 2000) many 
are found within the same cell and in-vitro have broadly overlapping substrate 
specificities. It has, therefore, been suggested that substrate specificity could be 
mediated by the localization of individual isoforms to specific subcellular 
compartments. Since there is a high sequence conservation within the C-terminal kinase 
domain it has been proposed that relatively small sequence motifs or signal patches 
found in the N-terminal regulatory domain and variable regions contribute to the 
isoform specific interactions and consequent signal diversity. Consistent with this 
hypothesis, kinase domain swapping experiments in Drosophila show that the kinase 
domain of PKC53E can functionally substitute for the kinase domain of protein kinase 
C-related, Pkn (the most closely related AGC kinase, (Palmer et al., 1994, Kitagawa et 
al., 1995) suggesting that it is the N-terminus of Pkn that localizes the PKC53E kinase 
domain to a particular subcellular region and that the kinase domain simply does its job 
there (Betson and Settleman, 2007).  
Even so, how can the specific function of each PKC isoform be determined 
unequivocally? Currently, the most exquisitely specific approach employed for 
perturbing kinase activity is that of a chemical genetic approach, pioneered by the 
Shokat laboratory (Bishop et al., 1998, Bishop et al., 2000, Alaimo et al., 2001). A 
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conserved residue that sits in the bottom of the ATP-binding pocket and termed the 
‘gatekeeper’ can be exploited to generate mutants that are specifically inhibited by 
kinase inhibitor analogues (Figure 1.8). Point mutation of the bulky gatekeeper to a 
small residue such as Gly or Ala renders the kinase almost uniquely sensitive to 
sterically bulky analogues of naturally occurring kinase inhibitors. Wild type kinases, 
which retain their bulky gatekeeper residues, are resistant to such inhibition. Indeed this 
strategy has been useful in determining the physiological role of the regulated PKCε-
14.3.3 complex assembly, see below (Saurin et al., 2008). It is notable, however, that a 
mutation of this kind can impair the activity or ATP binding potential of the kinase. A 
reduced affinity for ATP in the gatekeeper mutant PKCε-M486Ais reflected in the 
relative instability of the priming phosphorylations. In contrast to PKCε-WT, PKCε-
M486A exposure to PMA induces substantial dephosphorylation of all three priming 
sites within 30 minutes (Cameron et al., 2009).  
A chemical genetic approach using Src kinase inhibitor analog, 4-amino-1-tert-butyl-3-
(1’naphthyl)-pyrazolo[3,4-d] pyrimidine, NaPP1 (Qi et al., 2007, Durgan et al., 2008) to 
target mutant, PKCε-M486A provided the opportunity to confirm a role for PKCε in 
cytokinesis (which was initially identified in 14.3.3 binding defective and kinase 
defective mutants) and also permitted the monitoring of the localization of GFP-PKCε-
M486A. Under conditions of selective inhibition, PKCε-M486A was shown to localize 
at the cytokinetic furrow/midbody with polymerized actin, active RhoA and an 
accompanying delay in cytokinesis. Indeed accumulated PKCε-M486A was shown to 
persist for several hours after which time the cells either separated or failed and instead 
formed a single binucleate cell (Saurin et al., 2008). Furthermore, the retention of 
RhoA-GTP on treatment of GFP-PKCε-M486A cells with NaPP1 is indicative of a role 
in RhoA inactivation and consequent control of actin depolymerization (Saurin et al., 
2008).  
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Figure 1-8 A chemical genetic approach for selectively inhibiting PKCε   
WT kinases generally have a hydrophobic gatekeeper residue making inhibition 
difficult. Point mutation of M486A in PKCε renders the kinase almost uniquely 
sensitive to a sterically bulky analogue of ATP, in this case NaPP1. Although the 
schematic is shown depicting the inhibition of PKCε, this strategy is applicable to most 
protein kinases.  
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As previously mentioned, PKCε could mediate its function here by driving the control 
of a Rho GEF/GAP or RhoA itself.  Alternatively, PKCε may contribute to the aurora B 
undefined sensor complex that responds to unsegregated chromatin at the cleavage site 
by delaying abscission (Steigemann et al., 2009). Consistent with a function of PKCε in 
mediating checkpoint control, recent work in the laboratory has shown that PKCε plays 
an important role in a metaphase to anaphase surveillance mechanism that is sensitive to 
unresolved metaphase catenation (Brownlow et al In Preparation), whether this is an 
extension of the SAC or precedes that of the aurora B mediated cytokinesis checkpoint 
however, remains to be defined. Interestingly, loss of PKCε function results in a large 
number of lagging chromosomes in anaphase, in principle the inhibition of PKCε-
M486A by NaPP1 might act to induce a similar response that then becomes evident 
only at the point of RhoA inactivation. In view of the critical role of PKCε in cell 
division it is, however, intriguing that a PKCε knockout mouse is viable. This is 
perhaps reflective of the redundant behaviour of PKC isoforms. In the absence of PKCε, 
it is plausible that the related PKCδ performs the appropriate function instead and this is 
consistent with the embryonic lethality of a PKCε/δ double knockouts (unpublished).  
In an attempt to resolve how PKCε control is exerted during cytokinesis it is imperative 
that we define a detailed molecular pathway which would include the signal input 
required for PKCε action and its consequent associations, the mechanism by which 
PKCε is localized and retained at the furrow/midbody and whether it controls RhoA-
GTP loading and the mechanism by which it does so. 
 
1.4.2 PKCε localization at the cytokinetic furrow/midbody 
 
With regards to PKCε localization at the furrow/midbody, there are several motifs 
located within the N-terminal region of PKCε which may mediate this accumulation 
(Figure 1.9). Potential candidates include the V3 hinge region motifs responsible for 
binding 14.3.3 and selective targeting to cell-cell contacts (Quittau-Prevostel et al., 
2004). In view of the role of actin in cytokinesis, the unique actin binding motif,  
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Figure 1-9 Schematic of PKCε showing domains and post-translational 
modifications 
Critical residues highlighted in red, see main text.   
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LKKQET (Prekeris et al., 1996, Prekeris et al., 1998) located in the region between the 
C1A and C1B domains (herein referred to as the inter-C1 domain, IC1D) is also a 
plausible candidate. 
 
1.4.3 PKCε and 14.3.3 binding 
 
14.3.3 proteins are an abundant family of 28-33kDa proteins that exist as homo-or in 
hetero-dimers prior to interaction with a diverse array of cellular proteins (Morrison, 
2009). At least 100 proteins have been found to interact with 14.3.3 isoforms including 
PKCs, Raf family members and receptor proteins (glucocorticoid receptor and insulin-
like growth factor I receptor). In mammalian cells, seven isoforms (β, ε, γ, η,σ, τ and ξ) 
have been identified (Yaffe et al., 1997). All actions of 14.3.3 involve binding to target 
proteins, which typically involves recognizing the phosphorylation of specific Ser or 
Thr residues within either a mode I motif (RSXpSXP) or a mode II motif (RXXXpSXP, 
Yaffe et al., 1997). Successful binding has been shown to affect protein localization (Lo 
et al., 2004, Douglas et al., 2010), stability (LeBron et al., 2006) and/or activity (Obsil 
et al., 2001) thereby influencing cell adhesion (Han et al., 2001), cell polarity (Benton et 
al., 2002), cell survival (LeBron et al., 2006) and cell cycle (Douglas et al., 2010). 
Recently, it has been described that 14.3.3 functions during the late stages of mitosis, 
where its association with PKCε is required for the completion of cytokinesis (Saurin et 
al., 2008). Whether this particular control relates to the earlier 14.3.3 inhibition of 
centralspindlin remains to be determined (Douglas et al., 2010).  
The defined PKCε-14.3.3 interaction is dependent on PKCε phosphorylation at 3 
distinct V3 domain sites (situated between the regulatory and catalytic domains). 
Specifically; a glycogen synthase kinase-3 (GSK3) site (S346) matching the consensus 
14.3.3 mode I site, an autophosphorylation site (S368) that is related to a mode II 
binding motif and a priming phosphorylation on PKCε targeted by p38 MAPkinase at 
S350 (required for the phosphorylation at S346,(Saurin et al., 2008). The structure of 
this phosphorylated V3 domain complexed to 14.3.3 has also been solved and shows a 
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1:2 hetero-trimer formation (Kostelecky et al., 2009). The authors propose that the 
binding of 14.3.3 to the V3 hinge region of PKCε acts as a conformational clamp to 
lock the enzyme in an active open conformation and this is consistent with data 
displaying constitutive lipid-independent activity. With regards to its physiological role, 
the 14.3.3 interaction is required for the exit from cytokinesis as exemplified by the 
PKCε mutant S346/368A, which unlike the wild-type protein does not rescue 
cytokinetic defects after PKCε knockdown (Saurin et al., 2008).  
 
1.4.4 PKCε and selective targeting to cell-cell contacts 
 
Cells are connected to their neighbours in a highly ordered manner mediated by well-
organized macromolecular structures. The components of these adhesion complexes 
include a transmembrane protein (a cadherin) and numerous cytoplasmic proteins (α, β 
and γ-catenins Ozawa et al., 1989, Aberle et al., 1996), vinculin (Hazan et al., 1997) and 
α-actinin (Knudsen et al., 1995). The most common type of intercellular adhesion 
involves E-cadherin, which in the presence of Ca2+ can establish homophilic 
interactions at the site of cell-cell contacts (Takeichi, 1991). The cytoplasmic tail of E-
cadherin binds β-catenin, which in turn binds α-catenin and links the cytoskeleton by 
itself binding to actin. Unfortunately, the nature of the E-cadherin mediated signaling 
events are still largely unknown. However, it has been reported that PKCε, alongside 
PKCα, is found to accumulate selectively at cell-cell contacts in mouse pituitary glands, 
the rat pituitary GH3B6 cell line and at contacts between fibroblasts and epithelial cells 
upon either physiological or pharmacological activation (Collazos et al., 2006, Louis et 
al., 2005, Quittau-Prevostel et al., 2004). This is of interest because during the 
cytokinetic furrowing process the presumptive daughter cell plasma membranes become 
juxtaposed in a manner that might trigger conventional cell-cell contact responses.  
A three amino acid motif, GEE, located in the V3 region of PKCε is essential for 
selective targeting to cell-cell contacts (Quittau-Prevostel et al., 2004). An E374G point 
mutation abolishes any such selectivity and suggests that Glu374 is essential for proper 
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targeting (GDE and Asp294 in PKCα). However, this motif is not sufficient as 
replacing a Phe by Glu (GFE → GEE) at the equivalent position in PKCδ does not 
induce its targeting to cell-cell contacts. Currently, the role of PKCε at cell-cell contacts 
and the exact molecular events involved in the selective targeting remain unknown. 
However the pathophysiological consequences of abolishing cell-cell contact targeting 
are perhaps suggested in human pituitary and thyroid tumours where the naturally 
occurring PKCα D294G mutant is found (Alvaro et al., 1993, Prevostel et al., 1995). 
 
1.4.5 PKCε and actin binding 
 
Actin is one of the most highly conserved and abundant proteins in eukaryotic cells and 
many cellular processes (including cell motility, endocytosis and cytokinesis) are 
powered by its rapid polymerization (reviewed in Campellone and Welch, 2010, Firat-
Karalar and Welch, 2011). Whilst cells typically contain a large pool of actin monomers 
(G-actin), spontaneous actin self-assembly is inefficient and to initiate assembly into a 
filamentous form (F-actin), cells generate free barbed ends that act as templates for 
polymerization by uncapping or severing existing filaments or by nucleating from 
monomers de novo using a diverse set of actin-nucleating proteins, including the actin-
related protein 2/3 (Arp2/3) complex, formins and tandem-monomer-binding 
nucleators. During cytokinesis, the formins have been found to be of functional 
importance, most notably during actomyosin contractile ring assembly (Castrillon and 
Wasserman, 1994, Swan et al., 1998, Watanabe et al., 2008). Formins are multidomain 
proteins that are defined by the conserved formin homology (FH) domains, FH1 and 
FH2, which function to assemble unbranched actin filaments, which is in contrast to the 
first discovered actin nucleator,  Arp2/3, forming a Y branched network (Rouiller et al., 
2008). Crystal structures of both yeast (Xu et al., 2004) and mammalian formins (Lu et 
al., 2007) in combination with mutant analysis (Moseley et al., 2004, Copeland et al., 
2004) suggest a model in which dimeric FH2 associates with the barbed end of an actin 
filament to promote actin filament stabilization. The proline-rich FH1 then stimulates 
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elongation by binding to profilin-actin (Romero et al., 2004) which serves to increase 
the local concentration of G-actin at the barbed end (Vavylonis et al., 2006).  
Previous studies have revealed that the key formin in assembly of the mammalian 
contractile ring at the equatorial cortex is diaphanous-related formin, mDia (Watanabe 
et al., 2008), of which there are three isoforms, mDia1,mDia2 and mDia3 (Higgs and 
Peterson, 2005).  Among these, mDia2 has been found to be essential in cytokinesis, 
selectively localising to the cleavage furrow and functioning downstream of the small 
GTPase RhoA (Watanabe et al., 2008).  Interestingly on RhoA inactivation mDia2 
localizes to the central spindle suggesting, like many other RhoA effectors, it responds 
to Rho signalling with translocation from the central spindle to the equatorial cortex 
(Watanabe et al., 2010). In addition, anillin, a scaffolding protein that can bind F-actin 
and is required for furrow stability and midbody formation (Field and Alberts, 1995, 
Somma et al., 2002, Echard et al., 2004) also binds mDia2 to further stabilize its 
localization and activation (Watanabe et al., 2010). Once assembled, the F-actin 
network then drives constriction of the furrow (see 1.2.4) and the depolymerization of 
actin at the end of cytokinesis is then associated with RhoA inactivation.  
In view of the complex regulation of actin and RhoA, it is intriguing that inhibition of 
PKCε leads to its accumulation at the furrow/midbody with polymerized actin and 
RhoA (Saurin et al., 2008). This may reflect a requirement for PKCε in this pathway 
also. PKCε is unique among the PKC isoforms in containing an F-actin binding motif 
(Prekeris et al., 1996). The hexapeptide (LKKQET) is located within the inter-C1 
domain (IC1D) at amino acids 223-228 and is required for the physical interaction 
between PKCε and F-actin. Deletion of amino acids encompassing this motif, 222-230, 
completely abrogates this binding activity (Prekeris et al., 1996) Despite the lack of 
structural evidence for a PKCε-actin interaction, the structure of actin-ciboulot complex 
reveals how an actin-binding motif, of similar sequence to that in PKCε, can bind in a 
hydrophobic cleft formed between actin subdomains (Hertzog et al., 2004). Currently, 
the functional roles associated with the assembled complex appear to be important for 
glutamate exocytosis from nerve terminals and outgrowth of cellular protrusions in 
fibroblasts (Hernandez et al., 2001). 
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1.4.6 PKCε and Cancer 
 
Indeed substantial evidence exists implicating PKCε as a transforming oncogene 
(reviewed in Gorin and Pan, 2009). Its overexpression in vitro has been shown to 
increase proliferation, motility and invasion of both fibroblasts and immortalised cells 
(Mischak et al., 1993, Cacace et al., 1993). Furthermore, xenograft and transgenic 
animal models demonstrates the aggressive metastatic phenotype PKCε establishes 
when overexpressed (Perletti et al., 1996). Arguably, the most conclusive result 
supporting a role for PKCε in carcinogenesis is that PKCε has been found 
overexpressed in tumour derived cell-lines and histopathological tumour specimens 
originating from a variety organs (including: bladder, brain, breast, lung, prostate, head 
and neck, Varga et al., 2004, Sharif and Sharif, 1999, Pan et al,. 2005, Bae et al., 2007, 
Aziz et al., 2007, Martinez-Gimeno et al., 1995).   
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Objectives 
PKCε has been recently uncovered as a key regulator acting at the end stage of 
cytokinesis (Saurin et al., 2008), while the evidence indicates that it functions to trigger 
RhoA inactivation and consequent actin depolymerization, the precise mechanism 
remains unclear. Defining the mechanism by which PKCε is localized to the 
furrow/midbody may shed light on how PKCε control is exerted during cytokinesis and 
more importantly whether intervention in this process might bring about benefits in the 
treatment of cancer. Please see Figure 1.10 for a model outlining the current 
understanding of PKCε regulation and localization.  
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Figure 1-10 Schematic summarizing how PKCε localization is controlled  
 (Reprinted and adapted with permission from Macmillan Publishers Ltd: Nature Cell 
Biology, Saurin et al, 10, 891-901, 2008). 1) The GEE motif selectively targets PKCε to 
cell-cell contacts. 2) Phosphorylation by PKC, p38 and GSK3 and membrane 
recruitment mediates PKCε-14.3.3 complex assembly (3). This complex then 
accumulates at the midbody where it is thought to control RhoA-GTP loading and 
consequent actin depolymerization.  
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Chapter 2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 General 
 
All reagents were obtained from Sigma Aldrich unless otherwise stated. Restriction 
enzymes were purchased from New England biolabs and kits for the purification of 
DNA were from Qiagen. Dulbecco’s Modified Eagle Medium (DMEM), penicillin, 
streptomyocin and Opti-MEM were obtained from Gibco and foetal-calf serum (FCS) 
was from PAA laboratories. Methanol (MeOH), ethanol (EtOH) and Trizma base were 
purchased from Fisher. Rabbit skeletal muscle actin and corresponding buffers were 
from Cytoskeleton. For a list of the pharmacological agents used and their supplier 
please see table 2.1. Similarly, for antibodies, see table 2.2 and 2.3 for primary and 
secondary respectively.   
All glassware was supplied by CR-UK research services and plasticware was purchased 
from Eppendorf, Corning, BD Falcon, Sterilin and Scientific Specialities. Glass bottom 
dishes for use in live microscopy were obtained from MatTek Corporation.  
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2.1.2 Buffers 
 
DNA loading buffer  
0.25% (w/v) bromophenol blue, 40% (w/v) sucrose in water 
LB (Agar)  
Provided by CR-UK research services. 10 g L-1 bacto-tryptone, 5 g L-1yeast extract, 10 g 
L-1 NaCl (6 g agar/400 ml LB).  
LBamp/kan (Agar) 
100 µg ml-1 ampicillin/25 µg ml-1 kanamycin in LB (Agar) 
LB (Broth) 
Provided by CR-UK research services, 10 g L-1 bacto-tryptone, 5 g L-1yeast extract, 10 g 
L-1 NaCl 
LBamp/kan (Broth) 
100 µg ml-1 ampicillin/25 µg ml-1 kanamycin in LB (Broth) 
2 x LDS Sample Buffer 
50% (v/v) 4 x LDS Sample Buffer (Invitrogen), 0.2 M DTT 
Lysis Buffer 
50 mM Tris, pH 7.4, 150 nM NaCl, 0.5% NP40 
Kinase Assay Mix 
20 mM Tris pH 7.5, 10 mM MgCl2, 1 mg ml-1 protamine sulphate, 100 µM ATP and 2.5 
mCi [γ-32P] ATP (added last to start the reaction, Amersham) 
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Kinase Dilution Buffer 
20 mM Tris pH 7.5, 2 mM EDTA, 5 mM DTT, 0.02% Triton-X 100 
PBS (Ca2+/Mg2+ free) 
Provided by CR-UK research services. 8 g L-1 NaCl, 0.25 g L-1 KCl, 1.43 g L-1 
Na2HPO4, 0.25 g L-1 KH2PO4, pH 7.2 
TBS 
200 mM Tris pH 7.5, 0.9% (w/v) NaCl 
TBS-T 
0.1% (v/v) Tween-20 in TBS 
TAE 
0.04 M Tris, 0.1% glacial acetic acid, 1 mM EDTA  
Transfer Buffer 
20 mM Trizma base, 200 mM Glycine, 10% MeOH 
5% Trypsin/Versene 
Provided by CR-UK research services. 0.25% trypsin in versene, pH7.2, filter sterilised.  
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2.1.3 Pharmacological agents 
Regent Supplier Solvent [Stock] [Working] 
Bisindolylmalemide-1 
(BIM1) 
Calbiochem DMSO 2 mM  1 µM 
Latrunculin A (LatA) Invitrogen DMSO 1 mM  100 nM 
4-amino-1-tert-butyl-3-
(1’natphthyl)-
pyrazolo[3,4-d] 
pyrimidine (NaPP1) 
Calbiochem DMSO 10 mM 4 µM 
Phorbol 12-myristate 13 
acetate (PMA) 
Sigma DMSO 1.6 mM 100 nM 
400 nM 
Table 2-1 Pharmacological agents  
Pharmacological agents used throughout this thesis. The working concentrations were 
chosen either in accordance with current literature or identified through titration 
experiments.  
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2.1.4 Antibodies 
2.1.4.1 Primary antibodies 
Name  Supplier Antigen  Use  Dilution  
Goat anti- 
Actin (I-19) 
sc-1616 
Santa Cruz 
Biotechnology 
Actin          
C-terminus 
Western Blot (WB) 1:1000 
Mouse anti-
β-catenin 
BD 
Transduction 
Laboratories  
β-catenin Immunofluorescence 
(IF) 
1:100 
Mouse anti- 
GFP 3E1 
CR-UK GFP IF 1.500 
Mouse anti- 
RhoA 
(26C4)      
sc-418 
Santa Cruz 
Biotechnology 
RhoA IF 1:100 
Mouse anti- 
Tubulin 
Sigma Tubulin  WB                           
IF 
1:5000  
1:500 
Rabbit anti- 
Ect2 (C-20) 
sc1005 
Santa Cruz 
Biotechnology 
Ect2           
C-terminus 
IF 1:100 
Rabbit anti- 
Lap2         
(H-130)     
sc-28541 
Santa Cruz 
Biotechnology 
Lab2 IF 1:100 
Rabbit anti- 
MKLP1    
(N-19)       
sc-867 
Santa Cruz 
Biotechnology 
MKLP1     
N-terminus 
IF 1:100 
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Rabbit anti- 
PKCε (C-15) 
sc-214 
Santa Cruz 
Biotechnology 
PKCε  
C-terminus 
WB 
IF 
1:1000 
1:100 
Rabbit anti- 
PKCε p729 
Millipore PKCε p729 WB 1:1000        
(+ 1 µg ml-1 
blocking de-
P peptide) 
Table 2-2 Primary antibodies 
Primary antibodies used throughout this thesis.  
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2.1.4.2 Secondary antibodies 
Name  Provider Use  Dilution  
Alexa-Fluor-
488 anti-
mouse 
Invitrogen IF 1:500 
Alexa-Fluor-
488 anti-
rabbit 
Invitrogen IF 1:500 
Alexa-Fluor- 
543 anti-
mouse 
Invitrogen IF 1:500 
Alexa-Fluor-
647 anti-
mouse 
Invitrogen IF 1:500 
Alexa-Fluor- 
647 anti-
rabbit 
Invitrogen IF 1:500 
Alex-Fluor-
555 
phalloidin  
Invitrogen IF 1:500 
Donkey anti-
rabbit HRP 
GE Healthcare WB 1:5000 
Donkey anti-
Goat HRP 
Santa Cruz 
Biotechnology 
IB 1.5000 
IRDye 
680LT    
anti-mouse  
Li-COR 
Biosciences 
WB 1:10000 
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IRDye 
800CW    
anti-rabbit 
Li-COR WB 1:10000 
Sheep anti-
mouse HRP 
GE Healthcare WB 1;5000 
Table 2-3 Secondary antibodies 
Secondary antibodies used throughout this thesis. 
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2.2 Methods 
 
2.2.1 Molecular biology 
 
2.2.1.1 Polymerase Chain Reaction  
 
Polymerase chain reactions (PCRs) were performed using a DNA Engine Dyad (MJ 
Research). The reaction mix used was as follows: 1 µl Pfu Ultra (Stratagene), 2.5 µl 10 
x Pfu buffer (Stratagene), 2.5 µl 10 mM dNTPs, 2 x 100 pmol primer and 10 ng DNA 
template, made up to 25 µl in distilled water. The programme used was as follows, 
unless otherwise specified:  
Step 1: 94°C, 5 mins 
Step 2: 94°C, 10 secs 
Step 3: (lowest primer Tm – 3)°C, 1 minute 
Step 4: 72°C (length of product in bps/500) mins 
 Cycle back to step 2 x 30 
Step 5: 72°C, 10 mins 
Step 6: 6°C hold  
PCR products were examined by agarose gel electrophoresis (see below) and purified 
using either the QIAquick Gel Extraction Kit or the QIAquick PCR Purification Kit 
according to the manufacturer’s instruction.  
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2.2.1.2 Restriction digests 
 
Restriction digests were performed in accordance with the manufacturer’s instruction.  
 
2.2.1.3 Agarose gel electrophoresis and gel purification 
 
Samples were diluted in a 5:1 volume ratio in DNA loading buffer and separated on a 
0.8% agarose gel, supplemented with 1 µM ethidium bromide, in 1x TAE buffer. 
Samples were run alongside a 1kb DNA ladder (Invitrogen). The DNA bands were 
visualised on a UV light box (254 nm wavelength) and excised as required. DNA 
extraction and purification were performed using the QIAquick Gel Extraction Kit.  
 
2.2.1.4 Ligation 
 
The ligation reaction mix used was as follows: 0.5 µl T4 DNA ligase (New England 
Biolabs), 2.5 µl 10 x ligase buffer (New England biolabs), 100 ng digested vector and 
an appropriate amount of insert DNA to achieve a typical 3:1 molar ratio (insert:vector). 
Ligation reactions were left overnight at room temperature.  
 
2.2.1.5 Transformation  
 
One Shot® chemically competent cells (Invitrogen) were transformed with purified 
plasmids or ligation reactions according to the manufacturer’s instructions. The 
transformation mix was plated on LB selective agar plates (LBamp or LBkan) and 
incubated overnight at 37°C.  
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2.2.1.6 DNA preparation 
 
A single transformed bacterial colony was inoculated into 5 ml LB selection media 
(LBamp or LBkan broth) and incubated overnight at 37°C with vigorous shaking. The 
culture was processed by the QIAprep Spin Miniprep Kit according to the 
manufacturer’s instruction and the purified DNA was sequenced (see below). For large 
scale DNA production, the starting culture was diluted 1:1000 into selection media 
(LBamp or LBkan broth) and incubated for a further 16 hours at 37°C with vigorous 
shaking. The culture was processed by QIAprep Spin Maxiprep kit according to the 
manufacturer’s instructions. The concentration of the purified DNA was measured by 
the NanoDrop 2000 (Thermo Scientific) and diluted to a stock concentration of 500 µg 
µl-1. 
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2.2.1.7 DNA sequencing 
 
DNA sequencing was performed using the BigDye® Terminator Kit (Applied 
Biosystems) according to the manufacturer’s instructions. The reaction mix used was as 
follows: 150 ng DNA template, 3.2 pmol primer (PKCε sequencing primers were from 
Dr Angus Cameron and were chosen so as to achieve full coverage) and 8 µl 
1xBigDye® Terminator Mix in sequencing buffer made up to a final volume of 20 µl in 
distilled water. The cycle sequencing programme used was as follows: 
Step 1: Ramp to 96°C at 2.5°C sec-1 
Step 2: 96°C, 1 min 
Step 3: 96°C, 10 sec 
Step 4: Ramp to (primer Tm – 3)°C at 1°C sec-1 
Step 5: (primer Tm – 3)°C, 5 sec 
Step 6: Ramp to 60°C at 1°C sec-1 
Step 7: 60°C, 4 min 
Cycle back to Step 3 x 24 
Step 8: 12°C forever  
To obtain clean sequencing data, the reaction products were purified using the 
DyeEx2.0 Spin Kit according to the manufacturer’s instructions. Sequencing was 
performed by CR-UK services on an Applied Biosystems 3730 DNA Analyser. The 
sequencing results were opened with Edit View software and analysed by DNA Strider 
software and Clustal W2 multiple sequence alignment. 
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2.2.2 Cloning 
 
The original cloning of the PKCε-WT cDNA into the pEGFP-C1 and pDsRed-
Monomer-C1 vector (Clontech) was performed by Dr Adrian Saurin, as was the site 
directed mutagenesis for PKCε-M486A and PKCε-S346/368A, in pEGFP-C1, using the 
Quick change XL kit (Stratagene). The subcloning of the GFP-PKCε-WT and GFP-
PKCε-M486A into the tetracycline inducible pcDNA5/FRT/TO© vector was performed 
by Dr Angus Cameron. 
GFP-PKCε-S346/368A was subcloned into the pcDNA5/FRT/TO© vector by 
manipulating the pcDNA5/FRT/TO©-GFP-PKCε-M486A plasmid. The GFP and first 
1204 base pair sequence were removed, leaving the M486A site, by digestion of the 
unique restriction sites Kpn1 and Afe1 and replaced with GFP-PKCε-S346/368A.  
The E374G point mutation was introduced into the pcDNA5/FRT/TO© GFP-PKCε-
M486A using the QuickChange XL kit according to the manufacturer’s instructions. 
The primers used to obtain the mutated E374G were as follows:  
Forward 5’-GACAACCGAGGAGGGGAGCACCGAGCG-3’ (GAG → GGG) 
Reverse 5’-CGCTCGGTGCTCCCCTCCTCGGTTGTC-3’  
The deletion mutagenesis for GFP-PKCε-ΔIC1D-M486A was performed using a 2-step 
PCR based mutagenesis approach (Figure 2.1). 
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Figure 2-1 2-step PCR base approach for the IC1D deletion mutant 
A schematic representation of the 2-step PCR based approach used for IC1D deletion 
mutagenesis. Primers are represented by arrows; red zigzags denote non-complementary 
sequences incorporating restriction sites for subsequent ligation reactions. Blue and 
purple (step 2) denote the overhangs created by the same coloured primer (from step 1). 
 
Briefly, primer F and 2 were used to amplify product a, primer R and 1 were used to 
amplify product b from a pcDNA5/FRT/TO©-GFP-PKCε-M486A template. Products a 
and b were purified by PCR purification, analysed by gel electrophoresis and used in 
combination as a template in PCR using F and R primers only.  
The primers used in construction of GFP-PKCε-ΔIC1D-M486A were as follows:  
F 5’-TAATAATAGGTACCCGCCACCATGGTGAGCAAG-3’,  [*][Kpn1][5’GFP] 
R 5’-ATTATTATGCGGCCGCCTCAGGGCATCAGGTCTTCACCAAA-3’ 
[*][Not1] [3’Eps] 
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1 5’ATTATTACAAAGTGCGCTGAGGTGGGCTCCCAACGG-3’,  
2 5’-CCGTTGGGAGCCCACCTCAGCGCACTTTGTAATAATGAGCT-3’ 
* Denotes non-complementary blank sequence. 
The M486A site was subcloned into the pDsRed-Monomer-C1 vector (Clontech) by 
manipulating the pcDNA5/FRT/TO©-GFP-PKCε-M486A plasmid, the PKCε 
surrounding the M486A site were removed by digestion of the unique restriction sites 
Afe1 and Not1 and replaced with M486A.  
mCherry-Histone 2B was kindly provided by Professor Daniel Gerlich, MARS-Lifeact-
RFP was from Dr Steven Cooper and mCherry-RhoA was a gift from Dr Eric Sahai.  
 
2.2.3 Mammalian cell culture 
 
2.2.3.1 Cell lines 
 
Human embryonic kidney 293 cells (HEK 293) were obtained by CR-UK research 
services. Flp-In™ T-Rex™-HEK 293 cells were purchased from Invitrogen. 
 
2.2.3.2 Cell culture and transfection 
 
Cells were cultured in DMEM containing 10% FCS, penicillin (50 units ml-1) and 
streptomycin (50 µg ml-1) at 37°C in a humidified 10% CO2 atmosphere. Flp-In™ T-
Rex™-HEK 293 cells were transfected with the pcDNA5/FRT/TO© vector encoding 
GFP-PKCε-WT, GFP-PKCε-M486A, GFP-PKCε-E374G-M486A, PKCε-S346/368A-
M486A and GFP-PKCε-ΔIC1D-M486A using the T-Rex™ system according to the 
manufacturer’s instructions. Polyclonal GFP-PKCε cell lines were then selected with 
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hygromycin B (50 µg ml-1, Invitrogen) for 4-6 weeks. To induce GFP-PKCε expression, 
cells were treated with tetracycline (100 ng ml-1) 24 hours prior to assay.  
The RFP-PKCε-M486A, cherry-H2B, MARS-lifeact-RFP and cherry-RhoA constructs 
were transiently transfected using Fugene 6 (Roche) according to the manufacturer’s 
instructions. Briefly, DNA and Fugene 6 in Opti-MEM were added directly to culture 
media 48 hours prior to imaging.   
 
2.2.4 Live confocal microscopy 
 
Cells were plated on poly-L-lysine coated 35 mm glass bottom dishes in DMEM 
containing 10% FCS, penicillin (50 units ml-1) and streptomycin (50 µg ml-1). To induce 
GFP-PKCε expression, cells were treated with tetracycline (100 ng ml-1) 24 hours prior 
to imaging. Cells were imaged using an inverted laser scanning confocal microscope 
(LSM 510, Carl Zeiss) using a Plan Apochromat oil immersion objective (x63, NA 1.4) 
and 488 nm/543 nm/585 nm excitation lines for GFP, RFP and mCherry respectively. 
The microscope was contained within a polymethylmethacrylate case and maintained at 
a constant temperature of 37°C with a 5% CO2 flow. Stacks were filmed every 30 
seconds for varying lengths of time and each frame (512 x 512) was comprised of 5 ‘Z’ 
sections averaged over 8 µm in the z axis Movies, representing a single 1 µm ‘Z’ optical 
section of cells were exported using the LSM software (Carl Zeiss).  
 
2.2.5 Fluorescence Recovery After Photobleaching 
 
Live-cell fluorescence recovery after photobleaching (FRAP) experiments were 
performed using the above microscopic set up. GFP-PKCε-M486A cells were incubated 
with NaPP1 (4 µM) for 10 minutes and EGTA (4 mM) was added as indicated. Each 
FRAP experiment comprised a sequence of 300 frames (128 x 128, pixel dwell time of 
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6.40 µs, pixel size 0.37 µm) including 10 pre-bleached frames. The bleaching process 
consisted of 100 iterations at 90% of bleach pulse (488 nm laser excitation, 30 mW) on 
a circular region of 2 pixels in area, within the midbody or at cell-cell contacts. 
Recovery was monitored by capturing a further 290 scans after the photobleach event. 
Quantification was performed using the FRAP module included in the LSM software 
(Carl Zeiss) and plotting the graphs to a best fit two exponential model I = I0 – I1 e-t/T1 – 
I2 e-t/T2. Where I0 is the intensity before bleach, I1 and I2 are the mobile fractions and T1 
and T2 the time constants. The average of 20 measurements are presented for all 
conditions and the data was analysed for statistical significance using student t-test.   
 
2.2.6 Optical trapping  
 
Trapping experiments were performed by John Phillips, Imperial College. Briefly, cells 
were detached from tissue culture coated flasks by treatment with accutase (PAA 
laboratories) for 5 minutes, followed immediately by dilution with DMEM containing 
10% FCS, penicillin (50 units ml-1), streptomycin (50 µg ml-1) and NaPP1/EGTA was 
added when indicated. Cells were then transferred to Sigmacote coated coverslips. Cells 
were trapped using a dual-optical trap system built onto the rear port of a Nikon 
TE2000-E microscope using a Plan Apochromat water immersion objective (x 60, NA 
1.2). The trapping beam (IPG Photonics) was fed into the microscope light pathway via 
a dichroic mirror beam splitter. Cells of equivalent size were trapped with 100 mW of 
laser power at the sample plane and brought into contact with each other. Still images of 
both brightfield and fluorescence were acquired prior to cell contact, at cell contact and 
at 5-10 minute intervals thereafter. The images were analysed with Vision Assistant 
software (National Instruments). A line profile was taken across both cells and the 
relative fluorescence across the system was plotted.  
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2.2.7 Immunofluorescence  
 
Cells were plated on acid-washed, poly-L-lysine coated coverslips in DMEM 
containing 10% FCS, penicillin (50 units ml-1) and streptomycin (50 µg ml-1). To induce 
GFP-PKCε expression, cells were treated with tetracycline (100 ng ml-1) 24 hours prior 
to assay (see figure legends for conditions of individual assays). Cells were then fixed 
in 4% paraformaldehyde/PBS (or 10% trichloroacetic acid/water for RhoA) for 15 
minutes, washed in PBS and then permeabilized and blocked using 0.2% Triton X-
100/2% BSA/TBS for another 15 minutes, all at room temperature. The coverslips were 
incubated with the described primary antibody (Table 2.2, diluted in 2% BSA/TBS) for 
1 hour at room temperature, washed 3 times in PBS and then stained using the described 
secondary antibody (Table 2.3, diluted in 2%BSA/TBS). The coverslips were washed 
twice more in PBS and once in water and mounted onto glass slides using Proglong® 
Gold Antifade Reagent (Invitrogen). Slides were stored at 4°C protected from light. 
Images were acquired using an upright laser scanning confocal microscope (LSM510, 
Carl Zeiss) using a Plan Apochromat oil immersion objective (x63, NA 1.4) and 405 
nm/488 nm/543 nm/633 nm excitation lines for DAPI, GFP, RFP and far red 
respectively. Individual channels were scanned sequentially and each image (1024 x 
1024) represents a single 1 µm ‘Z’ optical section of cells.  
 
2.2.8 Western blotting  
 
Cells were cultured in 6-well tissue culture coated plates in DMEM containing 10% 
FCS, penicillin (50 units ml-1) and streptomycin (50 µg ml-1). To induce GFP-PKCε 
expression cells were treated with tetracycline (100 ng ml-1) 24 hours prior to treatment 
as described in figure legends. On ice, cells were washed in PBS and harvested by 
scraping into 500 µl LDS sample buffer. Lysed samples were heated to 100°C for 10 
minutes (for actin cosedimentation preparation see below). SDS-PAGE was performed 
using the NuPAGE system with BisTris/4-12%-polyacryladmide gels and MOPS/SDS 
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running buffer according to the manufacturer’s instructions (Invitrogen). Samples were 
run alongside Full Range Rainbow Molecular Weight Markers (GE Healthcare). 
Proteins were transferred to methanol-soaked PVDF membranes (Millipore) using a 
Trans-Blot Cell (Bio-Rad) and transfer buffer. Immunoblots were blocked for 1 hour in 
TBST and 3% BSA and then incubated for a further hour with the described primary 
antibodies (diluted in 3% BSA/TBST). The membranes were then washed 3 times for 
10 minutes with TBST and incubated for one hour with the appropriate secondary 
antibodies (diluted in 5% non-fat dry milk/TBST). Following a final wash (3 times for 
10 minutes with TBST) bands were visualised by enhanced chemiluminescence 
(ECL®, GE Healthcare) and Kodak BioMax film or using the Odyssey infrared 
imaging system (LI-COR Biosciences) according to the manufacturer’s guidelines.  
 
2.2.9 Kinase assay 
 
Cells were cultured in 75 cm2 tissue culture coated flasks in DMEM containing 10% 
FCS, penicillin (50 units ml-1) and streptomycin (50 µg ml-1). To induce GFP-PKCε 
expression cells were treated with tetracycline (100 ng ml-1) 24 hours prior to assay. On 
ice. cells were washed in PBS and harvested by scraping into pre-chilled lysis buffer 
and complete protease inhibitor cocktail (Roche). Insoluble material was removed by 
centrifugation at 14,000 g for 5 minutes at 4°C and incubated with 20µl GFP trap beads 
(Chromotek) and rotated at 4°C for 1 hour. GFP bound complexes were washed 3 times 
in 1 ml lysis buffer at 4°C. To estimate PKCε concentration, samples were run 
alongside BSA controls in SDS-PAGE and were analysed by coomasie staining (see 
below).   
Kinase assays were performed in a total volume of 40 µl kinase assay mix with PKCε 
(or the equivalent volume for the control).  The reaction was started by the addition of 
ATP and incubated at 30°C with shaking. To stop the reaction, 15 µl of mix was spotted 
onto P81 phosphocellulose paper (Whatman) and washed 3 times for 5 minutes in acetic 
acid. The radioactivity was measured by Cerenkov counting in a Beckman LS6000IC 
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alongside stock ATP. All the reactions were performed in triplicate. In the assay pmol 
32P /min was calculated by: [(rc-b/sa) x 2.67]/10, where rc is raw counts incorporated 
into substrate, b is the average blank, 2.67 is a correction factor for transfer to 
phosphocellulose paper (15 µl spotted from a 40 µl sample) and 10 is the incubation 
time in min. The activity was converted from pmol 32P /min to pmol 32P /min/dish by 
multiplying by the overall dilution factor, 20. 
 
2.2.10 Coomassie blue staining 
 
SDS-PAGE gels were washed 3 x 5 minutes in distilled water and incubated in 20 ml 
GelCode Blue Stain Reagent (Thermo Scientific) at room temperature overnight with 
gentle shaking. Gels were destained in distilled water until bands were visible. Images 
were scanned using a MicroTek Scan Maker i700 and analysed using Image J 
quantification software.  
 
2.2.11 Actin cosedimentation  
 
Cells were cultured in 75 cm2 tissue culture coated flasks in DMEM containing 10% 
FCS, penicillin (50 units ml-1) and streptomycin (50 µg ml-1). To induce GFP-PKCε 
expression cells were treated with tetracycline (100 ng ml-1) 24 hours prior to assay. On 
ice, cells were washed in PBS and harvested by scraping into 1 ml pre-chilled lysis 
buffer with complete protease inhibitor cocktail (Roche). The lysates were pre-cleared 
by centrifugation at 100, 000 x g for 1 hour at 4°C. Freshly depolymerized rabbit 
skeletal muscle actin (50 µg) in actin buffer (200 µl, Cytoskeleton) were added to the 
resultant supernatant, along with 100 µl of polymerization buffer (Cytoskeleton) and 
samples were incubated for 1 hour at room temperature in the presence or absence of 
PMA as indicated. Samples were centrifuged at 100, 000 x g for 1 hour to precipitate 
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polymerized actin. The pellet fraction was solubilized in 20 µl LDS-Sample buffer and 
analysed by western blot (see above). 
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Chapter 3.  
 
Distinct kinetic properties of PKCε at the cytokinetic furrow/midbody and 
cell-cell contacts 
3.1 Summary 
 
PKCε has been shown to localize to cell-cell contacts and to juxtaposed membranes in 
the cytokinetic furrow/midbody under specific conditions. To assess the relationship 
between these two localization responses I have compared the behaviour of PKCε-
M486A during both processes. Using optical traps to manipulate cell-cell contacts, we 
have demonstrated that GFP-PKCε-M486A recruitment to these contacts is not 
modulated by the cell cycle and cannot be distinguished from that at the 
furrow/midbody. In contrast fluorescence recovery after photobleaching (FRAP) 
experiments have shown that GFP-PKCε-M486A furrow/midbody turnover is 
significantly slower than that at cell-cell contacts. This data indicates that despite the 
membrane juxtaposition of presumptive daughter cells at the furrow/midbody, the 
recruitment and/or retention of PKCε in this location is a distinct property and is not 
simply a reflection of cell-cell contacts.  
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3.2 Introduction 
 
All PKCs contain an amino-terminal regulatory domain and a carboxyl-terminal 
catalytic domain. In contrast to their variable regulatory domains, the catalytic domains 
are highly conserved, with each containing an ATP binding site and a protein substrate-
binding cleft (Mellor and Parker, 1998). The gatekeeper residue, which sits at the 
bottom of the ATP-binding pocket can be exploited to generate mutants that are 
specifically inhibited by kinase inhibitor analogues (Bishop et al., 2000). Point mutation 
of the bulky M486 residue within the ATP-binding pocket of PKCε (PKCε-M486A) 
renders the kinase almost uniquely sensitive to inhibition by the Src kinase-inhibitor 
analog, NaPP1 (Qi et al., 2007, Durgan et al., 2008). Interestingly, the selective 
inhibition of PKCε-M486A with NaPP1 causes localization of the enzyme at the plasma 
membrane and at the cytokinetic furrow/midbody. It has also been reported that 
activated PKCε, alongside PKCα, is found to accumulate selectively at cell-cell 
contacts in mouse pituitary glands, the rat pituitary GH3B6 cell line and at contacts 
between fibroblasts and epithelial cells upon either physiological or pharmacological 
activation (Collazos et al., 2006), (Quittau-Prevostel et al., 2004). While the initial 
plasma membrane recruitment is thought in part to be a function of DAG formation, the 
striking behaviour of PKCε at the furrow/midbody is possibly indicative of an 
interaction with a further membrane component(s) and this may relate to its 
accumulation at cell-cell contacts.  
During the furrowing process the presumptive daughter cells plasma membranes 
become juxtaposed in a manner that might trigger conventional cell-cell contact 
responses. If evidence is generated to indicate that only contact is required for 
furrow/midbody accumulation it means that PKCε behavior at the furrow/midbody 
becomes a much more simple model to dissect given that PKCε candidates involved in 
cell interactions, such as cadherins can be readily tested.  
Therefore, in this chapter, I address the relationship between cell-cell contact and 
furrow/midbody associated recruitment to determine whether the two are the same 
process. In collaboration with The Chemical Biology Centre, Imperial College, we use 
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optical traps to manipulate cell-cell contacts between interphase and mitotic cells and 
are able to show that recruitment of PKCε-M486A to these contacts is not cell cycle 
specific but cannot resolve whether the two processes are related. By contrast, analysing 
the dynamics of PKCε-M486A at cell-cell contacts and furrow/midbody by FRAP 
(Figure 3.1) I show that PKCε-M486A turnover at the furrow/midbody is slower than 
that at cell-cell contacts, which suggests a distinct recruitment and/or retention of PKCε 
at this compartment. In an attempt to probe regulatory differences, we discovered that 
dissociation of PKCε-M486A from cell-cell contacts in suspended cells is surprisingly 
dependent on Ca2+. 
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Figure 3-1 FRAP and its quantitative analysis   
A simple schematic is shown to illustrate the process of FRAP as applied to the 
experiments here addressing the turnover at the midbody. A strong laser beam is 
focused to a Region Of Interest (ROI, shown here as a red circle in the 
furrow/midbody). The strong irradiation bleaches the fluorescence in the ROI (shown 
here as a black circle). Bleached molecules can then be exchanged for unbleached 
molecules (from either the cytoplasm or plasma membrane) and the intensity of the ROI 
gradually recovers. Fluorescence recovery must be monitored over time and the 
resultant data fit using exponential equations (see results). Kinetic parameters can then 
be extracted from the graph.  
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3.3 Results 
 
3.3.1 Localization of PKCε-M486A at cell-cell contacts and 
furrow/midbody in response to NaPP1 
 
To address the question of whether PKCε recruitment to cell-cell contacts was related to 
the accumulation at juxtaposed membranes in the cytokinetic furrow/midbody, flp-in T-
Rex cells were used to generate tetracycline inducible expression of GFP-PKCε-WT 
and the NaPP1 sensitive gatekeeper mutant GFP-PKCε-M486A.  NaPP1 addition to 
induced M486A cells, as expected, leads to a transient membrane accumulation and a 
more sustained furrow/midbody accumulation in mitotic cells with a concomitant delay 
in the final stage of cytokinesis (Figure 3.2A, Video 1).  This cell-cell contact behaviour 
is in accordance with the pattern of response reported for PKCε in pituitary cells where 
agonist-dependent, transient, distributed membrane recruitment is followed by PKCε 
accumulation at cell-cell contacts (Quittau-Prevostel et al., 2004). In the absence of 
NaPP1, cells complete cytokinesis normally with no change in the distribution of GFP-
PKCε-M486A (Figure 3.2B, Video 2) or GFP-PKCε-WT (Figure 3.3). Similarly, 
NaPP1 addition to induced WT cells caused no change in the distribution of GFP-
PKCε-WT and cells complete cytokinesis normally, showing that the accumulation at 
the furrow/midbody seen upon NaPP1 addition is a result of specific GFP-PKCε-
M486A targeting (Figure 3.3).  
Optical traps were then employed on the model cell lines to compare interphase and 
mitotic behaviour, the latter of which were defined according to their dumbbell shape. 
Unfortunately, however, we haven’t been able to conclusively prove the mitotic nature 
of these cells. Nevertheless, using optical traps to manipulate cell-cell contacts it was 
evident that in the presence of NaPP1 GFP-PKCε-M486A accumulated at juxtaposed 
cell-cell contacts (Figure 3.4). In the absence of NaPP1 or with GFP-PKCε-WT 
expressing cells no evidence of cell-cell contact accumulation was observed.  
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C 
 
Figure 3-2 Selective inhibition of PKCε-M486A results in localization at the 
plasma membrane and cytokinetic furrow/midbody  
Still images, taken from a time-lapse video of 30 second intervals, of the M486A cell 
line in the presence of NaPP1 (4 µM, A) or the absence of NaPP1 (B).  A) Arrowheads 
in panel 2 indicate relative GFP accumulation at the plasma membrane whilst that in 
panel 3 is indicative of midbody accumulation in an actively dividing cell. Panel 4 is an 
enhanced image (magnified white box in panel 3, 2.5X) of this mitotic cell. This 
accumulation persists for several hours with a temporary arrest in cytokinesis. B) In the 
absence of NaPP1, cells complete cytokinesis normally with no change in the 
distribution of GFP. C) Quantification of PKCε-M486A and PKCε-WT accumulation at 
the furrow/midbody in the presence or absence of NaPP1, n=50.  
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Figure 3-3 PKCε-WT does not localize to the plasma membrane or the cytokinetic 
furrow/midbody  
Still images, taken from a time-lapse video taken at 30 second intervals, of the WT cell 
line in the presence of NaPP1 (4 µM, top) or the absence of NaPP1 (bottom). 
Regardless of treatment, cells complete cytokinesis normally with no change in the 
distribution of GFP.  
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A     B 
 
 
Figure 3-4 Selective inhibition of PKCε-M486A results in localization at cell-cell 
contacts in TRAP manipulated cells   
A) Fluorescence and false colour images of M486A suspended cells in the presence of 
NaPP1. (i) two interphase cells; (ii) one interphase and one mitotic cell; (iii) two mitotic 
cells. Mitotic cells have been defined here according to their dumbbell shape. B) 
Changes in accumulation of PKCε at the cell-cell interface between two interphase 
cells. The increase in relative fluorescence shown here indicates how much more PKCε 
is present at the interface compared to the rest of the cell.  
 
In these trapping experiments and those that follow, I prepared the biological samples 
and the trapping was carried out by John Phillips. I interpreted the resultant data.  
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3.3.2 Localization of PKCε-WT at the furrow/midbody in response to 
Bim1  
To ensure that PKCε‐M486A localization at the furrow/midbody is a consequence of 
specific PKCε inhibition and not merely an off-target effect of NaPP1 on PKCε‐M486A, PKCε-WT was exposed to the structurally distinct PKC inhibitor 
bisindolylmaleimide 1 (Bim1). Similar to the PKCε-M486A response to NaPP1, Bim1 
addition induced PKCε-WT furrow/midbody accumulation. Intriguingly, Bim1 
treatment did not mediate PKCε-WT accumulation at the plasma membrane, this 
perhaps reflects a dependence on other Bim1 sensitive activities for its retention here 
when inactive or a less efficient inhibition (Figure 3.5).  
 
3.3.3 FRAP experiments distinguish between the kinetics of PKCε-M486A 
at cell-cell contacts from that at the furrow/midbody 
 
The lack of any distinction between mitotic and interphase cells, however, did not 
resolve whether recruitment of PKCε-M486A to cell-cell contacts and the 
furrow/midbody were related. In an attempt to distinguish between the two I measured 
the dynamics of PKCε-M486A at cell-cell contacts and the furrow/midbody using 
FRAP in the presence of NaPP1. Given that this approach was not routinely used in the 
institute, I initially titrated the area of the region of interest (ROI) and bleach intensity 
of the highly focused laser beam. The area of the ROI was optimised so as to avoid a 
significant amount of interference in data collection as seen if the area is too small but 
to avoid photobleaching damage as a consequence of too large an area (see material and 
methods for dimensions). The bleach intensity was optimised so as to avoid a saturated 
photobleaching effect. Furthermore, maximal recovery was found by capturing scans 
over a 80s period and a similar extent of recovery was observed at both compartments. 
Figure 3.5A illustrates a typical set of recovery images from a FRAP experiment, whilst 
Figure 3.6B shows typical recovery curves from data gathered in  
Chapter 3. Results 
 90 
 
Figure 3-5 Inhibition of PKCε-WT results in localization at the cytokinetic 
furrow/midbody 
Still images, taken from a time-lapse video with 30 second intervals from the point of 
addition, of the WT cell line in the presence of Bim1 (1 µM). In the absence of Bim1 
see Figure 3.2.  
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Figure 3-6 PKCε-M486A turnover is significantly slower at the furrow/midbody 
than that at cell-cell contacts 
A) Typical images obtained from a confocal time series for cells pretreated with NaPP1. 
Cells were bleached at either a cell-cell contact or the midbody (indicated by white 
circle) and fluorescence recovery was monitored at 248 ms intervals over 70 s. B) 
Typical normalized recovery curves from (A) fitted to a double exponential model: 
.ee 21
210
TtTt
IIII
!!
!!=  C) Pooled data (n=20) for T1 and T2, determined as in (B), T1 values 
averaged at 2.25 s and 7.49 s for cell-cell contacts and midbody respectively and are 
significantly different (determined using a student t-test and the level of significance 
indicated here by  *).  T2 values are not significantly different (ns). 
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3.6A The recovery data of the mobile fraction were best fitted using the FRAP module 
in the LSM software (see materials and methods) and found to be of a better fit if 
plotted to a two exponential model as opposed to a one exponential model. Using such a 
model, two distinct kinetic components I1 and I2 with corresponding fast (T1) and slow 
(T2) recovery times, both of which are proportional to the time it takes for 50% of the 
fluorescence to be recovered, are determined. Indeed, use of a two exponential model is 
consistent with the populations of PKCε-M486A in existence.  There appears to be a 
fast diffusing cytosolic PKCε-M486A population (with a recovery time indicated by T1) 
and a much slower diffusing PKCε-M486A membrane population (with a recovery time 
indicated by T2). Pooled T1 and T2 values are shown in Figure 3.6C for each 
compartment. Although there is no significant difference between the pooled T2 values, 
which suggests an equal contribution from the plasma membrane PKCε population to 
the ROI at both cell-cell contacts and the furrow/midbody, there is a significant 
difference in the pooled T1 values. PKCε-M486A turnover at the furrow/midbody is 
significantly slower than at cell-cell contacts. The mean value for furrow/midbody 
recovery is 7.49±0.67 seconds compared with 2.25±0.2 seconds at cell-cell contacts, 
which suggests that these compartment retentions are distinguishable and are driven by 
distinct mechanisms. Furthermore, the kinetic analysis has been confirmed 
independently of the FRAP module on the LSM software by exporting the raw recovery 
data into Microsoft Excel with the appropriate formula pre-programmed, which corrects 
for background fluorescence, normalizes the resultant data and corrects for bleaching. 
The recovery curves were then plotted using a biexponential model pre-programmed 
into the Prism software. The resultant kinetics were found to be consistent with those 
obtained from the LSM software (see Appendix). 
 
3.3.4 A Ca2+-dependent PKCε-M486A ‘off rate’ at cell-cell contacts in 
suspended cells only 
 
To probe potential regulatory differences between the two recruitment processes, we 
assessed whether the production of DAG involved the classical Ca2+ dependent  PI-
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specific phospholipase C pathway. This was tested initially by depleting cells of Ca2+ 
using the Ca2+ chelator EGTA. In suspension (optical traps), Ca2+ depletion led to the 
unexpected sustained recruitment of PKCε-M486A at cell-cell contacts (Figure 3.7A). 
Given that the ‘on rate’ was found to be unchanged in the absence of calcium, we 
hypothesized that Ca2+ depletion acts to slow down the ‘off rate’ (Figure 3.7B).  
Consistent with a slower ‘off rate’ Ca2+ depletion produced cells with patches of plasma 
membrane GFP-PKCε-M486A that would may to be “echoes” of transient cell-cell 
contacts (Figure 3.8). Interestingly, these suspension cells proved considerably harder to 
separate in Ca2+ depleted culture medium (Figure 3.9). In contrast, although I observe a 
general trend in the increase of T1 values, there was no significant difference between 
PKCε-M486A dynamics at cell-cell contacts upon exposure to EGTA when compared 
to the corresponding mean T1 value in the presence of Ca2+. Nor was there any 
significant difference between the dynamics of PKCε-M486A at the furrow/midbody 
under the two conditions described (Figure 3.10).  Furthermore, there was no significant 
difference between pooled T2 values for the turnover of PKCε-M486A in the presence 
of absence of Ca2+ at either cell-cell contacts or the furrow/midbody. However, it is of 
particular note that for these FRAP experiments selective inhibition of PKCε-M486A, 
prior to EGTA exposure, was absolutely necessary as the depletion of Ca2+ in cells 
expressing active PKCε-M486A plated on poly-L-lysine led to cell shrinkage and 
disruption of cell-cell contacts (Figure 3.11, Videos 3 and 4). EGTA addition to ectopic 
WT PKCε expressing cells in the presence of NaPP1 (Figure 3.11, Videos 5 and 6), 
however, did not protect the cells from either shrinkage or cell-cell contact disruption. 
Similarly, a lack of protection was also observed for PKCε-M486A induced cells plated 
on fibronectin (Video 7 and 8), collagen (Video 9 and 10) or laminin (Video 11 and 12). 
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Figure 3-7 Sustained recruitment of PKCε-M486A at cell-cell contacts in TRAP 
manipulated cells upon exposure to EGTA 
A) Changes in accumulation of PKCε-M486A in the presence of EGTA (4 mM). B) 
Comparison of rates of accumulation in the presence and absence of EGTA. The 
addition of EGTA to the cells in the presence of NaPP1 (PP1) causes no change in the 
rate of accumulation, increasing the overall level of PKCε-M486A fluorescence rather 
than its accumulation rate.   
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Figure 3-8 Retention of PKCε-M486A at transient cell-cell contacts in TRAP 
manipulated cells is consistent with a slower ‘off-rate’  
Fluorescence image of M486A cells in the presence of both NaPP1 and EGTA, showing 
‘patches’ of PKCε-M486A accumulation. T1 indicates position of trap 1; T2 indicates 
position of trap 2 and P1, P2, P3 are examples of ‘patches’.  
 
        
Figure 3-9 Calcium depletion increases the strength of cell-cell contacts   
Cells were treated as indicated and optical forces applied to tease pairs of cells apart. 
The numbers of cell pairs able to be detached using optical traps is shown in the 
histogram. The definition of undetached pairs are those that could not be separated at 
the maximum trapping force of approximately 55pN. Detached cell pairs could be 
completely separated and manipulated independently. Semi-detached cell pairs could be 
separated to the extent that the cellular interface was no longer visible by eye but could 
not be independently manipulated.   
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Figure 3-10 PKCε-M486A turnover is not significantly different at either 
furrow/midbody or cell-cell contacts upon exposure to EGTA  
A similar approach was taken as in Figure 3.5. Pooled data (n=20) for T1 and T2 for all 
conditions described.  
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Figure 3-11 Calcium depletion leads to cell-shrinkage and cell-cell contact 
disruption unless pre-treated with NaPP1   
Still images taken from a time lapse video. Top panel indicative of M486A cells 
exposed to EGTA (4 mM) over a time course described. 2nd row represents M486A 
cells pre-treated with NaPP1 (4 µm, 10 minutes) and then EGTA (4 mM) over a time 
course described. WT cells exposed to EGTA (4 mM, 3rd row) have a similar phenotype 
as seen in M486A but there is no rescue of the EGTA phenotype in the presence of 
NaPP1 (bottom). 
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3.4 Discussion 
 
PKCε has been shown to localize to cell-cell contacts and to the cytokinetic 
furrow/midbody under conditions of PKCε-M486A inhibition (Figure 3.2), suggesting 
that in its active state PKCε retention at membrane compartments is poor and that 
catalytic activity is critical for its release. This was confirmed using Bim1 to target WT 
PKCε (Figure 3.5). We also show that in the presence of NaPP1, PKCε-M486A 
accumulates at juxtaposed cell-cell contacts (Figure 3.4). However, the lack of any 
distinction between mitotic and interphase cells did not resolve whether cell-cell 
contacts and furrow/midbody localization were related, to distinguish between the two I 
have used FRAP. Here, using a double exponential model which best fits the data, we 
consider there are two distinct populations, a fast diffusing cytosolic component (with a 
corresponding T1 recovery time) and a second much slower diffusing membrane 
population (with a T2 recovery time), I show that PKCε-M486A turnover is 
significantly slower at the furrow/midbody as compared with the turnover at cell-cell 
contacts, with mean T1s of 7.49 s and 2.25 s respectively (Figure 3.6). Thus I can 
conclude that the inactivity dependent furrow/midbody accumulation of PKCε-M486A 
in mitotic cells is not the same process as that at interphase cell-cell contacts. Rather, 
this instead represents a relatively infrequent event where the distinctive and more avid 
behaviour of PKCε-M486A is indicative of other factors contributing to its retention 
(see Chapter 4). It is notable however, that cell-cell contact related recruitment might 
still serve as a possible prelude to furrow/midbody accumulation and this too will be 
tested in the next chapter.  
In view of the role of DAG in PKCε plasma membrane recruitment it is plausible that 
membrane recruitment in cell-cell contacts and at the furrow/midbody is in part a 
function of DAG. To probe potential regulatory differences we assessed whether DAG 
was involved, via a Ca2+ dependent PLC pathway, by depleting Ca2+. Although a 
negative affect on the retention and/or dynamics was anticipated, it was surprising to 
find that Ca2+ depletion in cell suspension led to the sustained recruitment of inactive 
PKCε-M486A at cell-cell contacts (Figure 3.7) and produced cells with patches of 
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plasma membrane PKCε-M486A that would appear to be echoes of transient cell-cell 
contacts (Figure 3.8). If this is true, these domains maybe enriched with cell-cell contact 
specific proteins such as cadherins or β-catenin (see below). Alternatively, given the 
raft-like nature of these patches, this may represent an increase in lipid raft affinity of 
PKCε in the presence of EGTA. Currently, these explanations remain merely 
speculative. I have been unable to conclusively show the underlying mechanism. 
However, with no change in the ‘on rate’ of membrane contact accumulation (Figure 
3.7) it is hypothesized that Ca2+ depletion acts to slow down the ‘off rate’. 
Unfortunately, the FRAP analysis performed here provides conflicting evidence for 
Ca2+-dependent turnover of PKCε-M486A at cell-cell contacts. There was no evidence 
of any significant change to the mean T1 values for cell-cell contacts in the presence or 
absence of Ca2+ in FRAP experiments (Figure 3.10). This result may reflect the 
suspension behaviour of these cells and/or the nature of the cell-cell contacts in the two 
environments. For example, the transient nature of the cell-cell contacts in suspension 
may be fundamentally different from the sustained cell-cell contacts observed in culture 
especially with regard to the engagement of cadherins (see below).  
Given PKCε’s classification as a Ca2+-independent PKC with respect to membrane 
recruitment it is intriguing to find that dissociation of PKCε-M486A at cell-cell contacts 
is Ca2+ dependent in suspended cells. As there are almost no precedents for Ca2+ 
dependent behaviour of PKCε, I propose a scenario in which Ca2+ regulates PKCε 
interactors  specifically at cell-cell contacts where integrins are not (fully) engaged and 
this is then stabilized upon PKCε-M486A inhibition and Ca2+ depletion. Candidate 
PKCε partners include members of the cadherin family and their various cytoplasmic 
binding partners, given that collectively they are responsible for adhesive interactions 
via a Ca2+-dependent mechanism (Takeichi, 1991) and have been implicated in signal 
transduction via PKC (Lewis et al., 1994). Consistent with this proposed increase in 
stability, upon treatment with NaPP1 and EGTA, suspension cells proved considerably 
harder to separate and in cell culture, the cells were resistant to disruption of cell-cell 
contacts (Figure 3.9). Furthermore, in support of an integrin independent mechanism , 
Ca2+ depletion induced cell shrinkage is only PKCε-M486A controlled on poly-L-
lysine. If cells are plated on collagen, fibronectin or laminin which are adhesive 
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solutions that do engage integrins, this control is lost. To test the involvement of 
cadherins and their cytoplasmic binding partners, antibodies or siRNA directed at 
potential candidates could be tried and PKCε-M486A localization monitored under all 
the conditions described.  
Nonetheless, in this chapter I have shown that physical contact is sufficient to induce 
recruitment of PKCε-M486A to cell-cell contacts and retention here is, surprisingly, 
increased upon depletion of Ca2+ with EGTA. Furthermore, selective inhibition of 
PKCε-M486A protects 293 cells from EGTA cell-cell contact loss. Collectively, this 
indicates a role for PKCε in cell-cell contact maintenance. In addition, PKCε-M486A 
has a significantly slower turnover at the furrow/midbody that at cell-cell contacts 
which is indicative of a distinct regulatory mechanism. Attempts to further characterize 
this mechanism are now described in Chapter 4. 
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Chapter 4.  
 Recruitment of PKCε to the cytokinetic furrow/midbody 
 
4.1 Summary 
 
To assess the relationship between previously identified binding motifs within PKCε 
and PKCε-M486A furrow/midbody recruitment I have used a combination of 
mutagenesis and confocal microscopy. Using this approach I have shown that cell-cell 
contact targeting disruption does not alter GFP-PKCε-M486A furrow/midbody 
recruitment nor does furrow/midbody recruitment require 14.3.3 binding. Rather, 
localization is in part a function of a motif previously identified as a requirement for 
actin-binding, the IC1D. This implies an intriguing relationship between PKCε and the 
cytokinetic actomyosin ring.  
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4.2 Introduction 
 
In Chapter 3 I show that recruitment to the furrow/midbody and cell-cell contacts may 
not be through a common mechanism and consequently I have been unable to take 
advantage of the possibly easier route of analysing the abundant interphase cell-cell 
contacts. Instead, to determine how this relatively infrequent event is controlled a 
mutation study in PKCε-M486A using extensive live microscopy, has been employed. 
Given that small sequence motifs or signal patches found in the N-terminal and variable 
regions of PKCε have been proposed to contribute to its specific localization I have 
manipulated a variety of these and started to unravel the requirements and possible 
binding partners involved in PKCε-M486A furrow/midbody recruitment.   
In view of the evidence generated in chapter 3, it is notable, that cell-cell contacts may 
still serve as a possible prelude to furrow/midbody accumulation whereby the more 
distinct behaviour of PKCε reflect an interaction with further furrow/midbody 
components. The selective targeting of PKCε at cell-cell contacts can be attributed to a 
three amino acid motif located in the V3 hinge region, GEE, at residues 373-375 and a 
GEE to GGE mutation abolishes the selectivity of such targeting (Quittau-Prevostel et 
al., 2004). Interestingly, PKCε uniquely associates with 14.3.3 through its V3 hinge 
region also and PKCε-14.3.3 complex formation is required for the successful 
completion of cytokinesis (Saurin et al., 2008). Currently, the exact role of 14.3.3 in this 
complex remains unresolved and therefore it is plausible that 14.3.3 functions to 
influence recruitment of PKCε to the furrow/midbody. 14.3.3 binds to PKCε through 
the action of p38 and GSK3 which provide a phosphopeptide binding motif, termed 
mode 1, RSXpSXP at residues 343-348 whilst an autophosphorylation site produces a 
divergent mode 2 motif, RXXXpSXP, at residues 364-370. 14.3.3 binding to these 
motifs occurs in a cooperative, dimeric fashion as confirmed through crystallography 
and mutation. Indeed, mutations that prevent this association (PKCε-S346/368A, PKCε-
R343A) cause defects in the completion of cytokinesis (Saurin et al., 2008, Kostelecky 
et al., 2009). 
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PKCε is also unique among the PKC isoforms in containing an F-actin binding motif 
(Prekeris et al., 1996). This motif, LKKQET, is located inbetween the C1A and C1B at 
amino acids 223-228 and is predicted to become exposed upon PKCε activation. 
Deletion of amino acids encompassing this motif, 222-230/IC1D, completely abrogates 
this binding activity (Prekeris et al., 1998). Despite biochemical evidence confirming an 
actin-PKCε interaction, direct structural evidence remains elusive. Rather, the structure 
of an actin-WASP-homolgy domain 2 (WH2) complexes reveals how an actin-binding 
motif, of similar sequence to that in PKCε, can bind in a hydrophobic cleft formed 
between actin subdomains (reviewed in Dominguez, 2004). As the pocket remains 
accessible in F-actin (the predominant form of actin during furrow/midbody formation) 
it may represent the primary target for the LKKQET of PKCε during cytokinesis. 
Consistent with an actin-PKCε interaction during cytokinesis and a possible role in 
PKCε recruitment, here I show that recent evidence indicates that the selective 
inhibition of PKCε-M486A causes colocalization of the enzyme with actin at the 
furrow/midbody (Saurin et al., 2008). 
In this chapter I have addressed the relationship between these three binding motifs and 
PKCε-M486A furrow/midbody recruitment by generating these previously published 
mutations (E374G, S346/368A and Δ222-230/IC1D). In doing so, I demonstrate that 
PKCε-M486A recruitment is not cell-cell contact or 14.3.3 binding dependent. Rather, I 
show that localization is in part a function of the IC1D, a motif previously identified as 
actin-binding. 
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4.3 Results 
 
4.3.1 Cell-cell contact selective targeting is not required for PKCε-M486A 
furrow/midbody localization  
 
To address the question of whether cell-cell contacts serve as a prelude to PKCε-
M486A recruitment to the furrow/midbody, flp-in T-Rex cells were used to generate 
tetracycline inducible expression of the NaPP1 sensitive, cell-cell contact targeting 
mutant GFP-PKCε-E374G-M486A.  It is anticipated that manipulation of any of the 
critical motifs involved in PKCε-M486A recruitment will alter its retention at the 
furrow/midbody. As shown in Figure 4.1, the E374G mutation was sufficient to abolish 
the selectivity of targeting to cell-cell contacts upon PMA stimulation with the GFP 
signal evenly distributed at the contacted and uncontacted plasma membrane. However, 
this mutation was not sufficient to alter the accumulation of PKCε-M486A at the 
furrow/midbody. In a representative dividing GFP-PKCε-E374G-M486A expressing 
cell, NaPP1 addition leads to a transient membrane accumulation followed by a more 
sustained furrow/midbody accumulation and a concomitant delay in the final stage of 
cytokinesis (Figure 4.2).  This behaviour is entirely consistent with the pattern of 
response reported for PKCε-M486A in the previous chapter (Figure 3.2), suggesting 
that cell-cell contact associated functions doe not serve as a prelude to PKCε-M486A 
furrow/midbody localization. In the absence of NaPP1, cells complete cytokinesis 
normally with no change in the distribution of GFP-PKCε-E374G-M486A.  
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Figure 4-1 Immunofluorescent analysis of PKCε-M486A and PKCε-E374G-
M486A.  
M486A (A) and E374G –M486A (B) cells, after 10 minutes in the presence or absence 
of 100 nM PMA, were co-stained with anti-GFP and β-catenin. A selective 
translocation to cell-cell contacts was observed for PKCε-M486A. This selective 
targeting was lost in PKCε-E374G-M486A cells. C) Quantification of such targeting, 
where n=50.  
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Figure 4-2 Selective inhibition of PKCε-E374G-M486A results in localization at 
the plasma membrane and cytokinetic furrow/midbody.  
A)Still images, taken from a time-lapse video, of the E374G-M486A cell line in the 
presence of NaPP1 (4 µM). Progression through the time lapse (left to right) shows GFP 
accumulation at the plasma membrane and at the cytokinetic furrow/midbody, with an 
accompanying arrest in cytokinesis. B) In the absence of NaPP1, cells complete 
cytokinesis normally and there is no change in the distribution of GFP-PKCε-E374G-
M486A. Although a widefield image is shown, the dividing cell is highlighted within 
the white box and the panel furthest to the right has been enhanced to demonstrate this 
unchanged GFP distribution. C) Quantification of PKCε-E374G-M486A accumulation 
at the furrow/midbody in the presence or absence of NaPP1 and compared with PKCε-
M486A, n=20. 
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4.3.2 14.3.3 binding is not an absolute requirement for PKCε-M486A 
localization at the furrow/midbody 
 
To address the question of whether PKCε recruitment to the furrow/midbody was 
related to the binding of 14.3.3, flp-in T-Rex cells were used to generate tetracycline 
inducible expression of the NaPP1 sensitive, 14.3.3 binding mutant GFP-PKCε-
S346,368A-M486A (Saurin et al., 2008). It is of note, that the construct itself had been 
previously subjected to pull-down assays with GST-14.3.3.β beads by Dr. Adrian 
Saurin and was found to be devoid of 14.3.3 binding capabilities. In dividing GFP-
PKCε-S346,368A-M486A expressing cells, NaPP1 addition leads to a similar 
furrow/midbody accumulation of GFP-PKCε as seen previously using GFP-PKCε-
M486A and GFP-PKCε-E374G-M486A expressing cells. Cells halt at the final stage of 
cytokinesis whilst a transient membrane accumulation of GFP-PKCε-S346,368A-
M486A is promptly followed by a more sustained furrow/midbody accumulation 
(Figure 4.3). In the absence of NaPP1, cells complete cytokinesis normally with no 
change in the distribution of GFP-PKCε-S346,368A-M486A. The lack of any 
distinction between GFP-PKCε-M486A and GFP-PKCε-S346,368A-M486A suggests 
that 14.3.3 binding to PKCε is not responsible for furrow/midbody 
recruitment/retention. 
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Figure 4-3 Selective inhibition of PKCε-S346/368A-M486A results in localization 
at the plasma membrane and cytokinetic midbody/furrow. 
A) Still images, taken from a time-lapse video, of the S346/368A-M486A cell line in 
the presence of NaPP1 (4µM) Arrowheads in panel 3 (top row, from left to right) 
indicate relative GFP accumulation at the plasma membrane whilst that in panel 5 is 
indicative of furrow/midbody accumulation in an actively dividing cell. B) In the 
absence of NaPP1, cells complete cytokinesis normally with no change in the 
distribution of GFP-PKCε-S346/368A-M468A. C) Quantification of PKCε-S346/368A-
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M486A accumulation at the furrow/midbody in the presence or absence of NaPP1 and 
compared with PKCε-M486A, n=20. 
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4.3.3 PKCε -M486A plasma membrane and furrow/midbody localization is 
in part a function of the IC1D 
 
To assess the involvement of the actin binding motif, IC1D in PKCε recruitment to the 
furrow/midbody, flp-in T-Rex cells were used to generate tetracycline inducible 
expression of the NaPP1 sensitive, IC1D deletion mutant GFP-PKCε-ΔIC1D-M486A. 
In a representative dividing GFP-PKCε-ΔIC1D-M486A cell, the addition of NaPP1 
triggered no change in the distribution of GFP-PKCε-ΔIC1D-M486A and cytokinesis 
completes normally (Figure 4.4A, Video 13), in contrast to GFP-PKCε-M486A 
expressing cells. Furthermore, deletion of the domain prevents the kinase from 
accumulating at either the plasma membrane or furrow/midbody. Coexpressed RFP-
PKCε-M486A transiently expressed in the same cells (Figure 4.4B) is successfully 
recruited. 
 
4.3.4 A PMA and NaPP1 responsive PKCε -Δ IC1D-M486A is 
phosphorylated at S729 and is catalytically activity  
 
Although the nonapeptide sequence deleted from PKCε -ΔIC1D-M486A is critically 
located between the C1A and C1B, this mutation did not significantly alter its local 
topology or response to phorbol esters. Immunofluorescence microscopy was used to 
examine the GFP-PKCε-ΔIC1D-M486A response to PMA. In both the intact and 
mutated kinase staining for GFP in unstimulated cells was found diffuse throughout the 
cytoplasm whereas upon activation with PMA it selectively redistributed to cell 
membranes, indicative of an intact and functioning C1 domain (Figure 4.5).  
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Figure 4-4 Selective inhibition of PKCε-ΔIC1D-M486A does not result in 
localization at the plasma membrane or furrow/midbody 
A) Still images, taken from a time-lapse video, of the ΔIC1D-M486A cell line in the 
presence of NaPP1 (4 µM).  B) Coexpression of RFP-PKCε-M486A  with GFP-PKCε-
ΔIC1D-M486A cells ‘rescues’ the localization response to NaPP1. RFP-PKCε-M486A 
localizes to both the plasma membrane and to the furrow/midbody on exposure to 
NaPP1 (left column, 5 minutes post NaPP1, right column, 2 minutes later). C) RFP-
PKCε-M486A has no effect on GFP-PKCε-M486A localization. Coexpression of RFP-
PKCε-M486A with GFP-PKCε-M486A cells results in a colocalization of both RFP 
and GFP at the plasma membrane and furrow/midbody (left column, 5 minutes post 
NaPP1, right column 2 minutes later). C) Quantification of PKCε-ΔIC1D-M486A 
accumulation at the furrow/midbody in the presence or absence of NaPP1 and compared 
with PKCε-M486A, n=20. 
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Figure 4-5 Immunofluorescent analysis of PKCε-M486A and PKCε-ΔIC1D-
M486A 
M486A and ΔIC1D –M486A cells were simultaneously costained with anti-GFP, 
phalloidin and DAPI after 10 minutes in the presence (bottom half) or absence (top half) 
of 100 nM PMA. In unstimulated cells, GFP is found diffuse in the cytoplasm. 
Exposure to PMA induces translocation of GFP to the plasma membrane in both cell 
lines, as highlighted in the enhanced images (bottom two panels).  
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Work in the laboratory has previously demonstrated a reduced affinity for ATP in 
PKCε-M486A which is reflected in the instability of priming phosphorylations and 
exposure to PMA induces a substantial dephosphorylation at all three priming sites 
within 30 minutes. Treatment with NaPP1, however, promotes phosphorylation whilst a 
combinatorial approach protects the kinase from net dephosphorylation (Cameron et al., 
2009). To determine whether other indicators of normal functioning are in place for the 
IC1D, I analysed the priming phosphorylation in the S729 site. PKCε-ΔIC1D-M486A 
and PKCε-M486A expressing cells were treated with PMA, NaPP1 and a combination 
of both before being processed by Western blotting using the pS729 antibody (Figure 
4.6). Consistent with Cameron and colleagues, PKCε-M486A and PKCε-ΔIC1D-
M486A are similarly primed at S729 under basal conditions and the addition of NaPP1 
induces a small increase in phosphorylation. As expected, PMA induced a substantial 
dephosphorylation of this priming site in both proteins within 30 minutes whilst 
simultaneous treatment of NaPP1 and PMA entirely protects the kinases from net 
dephosphorylation. Despite a deletion of the IC1D, the data indicate that PKCε-ΔIC1D-
M486A retains priming site phosphorylations and is responsive to NaPP1. However, 
whilst it is clear that PMA causes loss of phosphorylation at the priming site in both cell 
lines, there is a differential effect on these two sties.  The less striking 
dephosphorylation of the ΔIC1D cell line may reflect a reduction in the efficiency in 
which the construct is recruited to the membrane. To assess catalytic funcion directly 
proteins were tested in vitro. Following immunopurification of GFP-PKCε-M486A and 
GFP-PKCε-ΔIC1D-M486A in vitro kinase assays were employed and these 
demonstrated that the mutant retained comparable kinase activity. 920 pmol min-1 dish-1 
and 860 pmol min-1 dish-1 for PKCε-M486A and PKCε-ΔIC1D-M486A respectively 
(Figure 4.7). 
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Figure 4-6 PKCε-ΔIC1D-M486A is primed at S729 and NaPP1 responsive 
Cells were treated with DMSO control, NaPP1(4 µM), PMA (400 nM) or a combination 
of both for 30 minutes before western blot analysis with anti-pS279 and GFP 
antibodies. Data normalized to GFP loading control showing that S279 is 
phosphorylated under basal conditions, phosphorylation is induced upon exposure to 
NaPP1 and PMA induces dephosphorylation in the both cell lines. Treatment with a 
combination of drug protects the kinase from net dephosphoryation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Results 
 118 
A 
 
Cells µg PKC Raw 
Counts 
pmol 32P 
/min 
Average Activity 
pmol/min/dish 
Control  0.8 eq 1904 0.1440785 <1 
       0.8 eq  1637 0.0941836 <1 
 0.8 eq 1702 0.1063303 <1 
 0.2 eq 781 -0.065779  
 0.2 eq 1546 0.0771782 0 
 0.2 eq 1000 -0.024854  
M486A 0.8 475050 88.561925 NL 
 0.8 281219 52.340294 NL 
 0.8 329517 61.36585 NL 
 0.2 210566 39.137211  
 0.2 300891 56.016445 922 
 0.2 232696 43.27269  
ΔIC1D 0.8 487620 90.910909 NL 
 0.8 453489 84.532773 NL 
 0.8 443441 82.655081 NL 
 0.2 256853 47.786966  
 0.2 137328 25.451063 863 
 0.2 302389 56.296379  
     
PKCε 
B 
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Figure 4-7 The kinase activity of PKCε-ΔIC1D-M486A is comparable to that of 
PKCε-M486A 
Figure 4.7 continued. An immunoprecipitation of the different forms of PKCε from 
cells followed by a kinase assay. A) Coomassie stain to roughly quantify protein 
concentration used in assay, PKCε calculated at approximately 1 µg for both M486A 
and ΔIC1D using Image J quantification software and BSA standard curve. B) 1 µg of 
PKCε, per triplicate, diluted as indicated, used in a kinase assay with protamine 
sulphate as the substrate. [γ-32P] incorporation over 10 minutes was analysed by 
Cerenkov counting. 0.8 eq and 0.2 eq represents an equivalent volume of pull down 
used in kinase assay for the control. NL denotes non-linear, as does the highlighted 
yellow cell based on substrate use of over 25%. Specific radioactivity (sa) of ATP 
(cpm/pmol) = 1427. In the assay pmol 32P /min was calculated by: [(rc-b/sa) x 2.67]/10, 
where rc is raw counts incorporated into substrate, b is the average blank, 2.67 is a 
volume correction factor for transfer to phosphocellulose paper and 10 is the incubation 
time in min. The activity was converted from average pmol 32P /min to pmol 32P 
/min/dish by multiplying by the dilution factor 20.    
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4.3.5 PKCε-Δ IC1D-M486A displays a weaker association with F-actin 
when compared to PKCε-M486A  
 
The ability of PKCε-ΔIC1D-M486A to bind F-actin was measured using 
cosedimentation assays and compared with that of ‘full length’ PKCε-M486A (Figure 
4.8). Briefly, PKCε lysates were incubated with polymerized actin for a period of one 
hour after which the samples were subjected to high-speed ultracentrifugation (see 
Materials and Methods). PKCε-ΔIC1D-M486A displays a weaker association with 
precipitated F-actin, when directly compared with PKCε-M486A, that is significantly 
enhanced by increasing the concentration of PMA. Of particular note, however, is the 
ability of recombinant PKCε to sediment even in the absence of actin, which reflects the 
difficulty in interpreting this assay. 
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Figure 4-8 Cosedimentation of purified F-actin with PKCε-M486A and PKCε-
ΔIC1D-M486A 
Cosedimentation of F-actin (50 µg) with PKCε-M486A and PKCε-ΔIC1D-M486A in 
the presence of varying concentrations of PMA. Supernatant and pellets were analysed 
by western blot and probed for PKCε and actin. PKCε can sediment even in the absence 
of polymerized actin (bottom panel).  
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4.4 Discussion 
 
In the previous chapter, I show that PKCε-M486A accumulation at the furrow/midbody 
is not the same process as that at cell-cell contacts, however the possibility that cell-cell 
contacts serve as a prelude to PKCε-M486A accumulation was not excluded. In this 
chapter, I have demonstrated that GEE motif required for selective targeting to cell-cell 
contacts does not mediate PKCε-M486A furrow/midbody accumulation (Figure 4.2). 
Rather the behaviour of PKCε-M486A at the furrow/midbody appears to be indicative 
of an entirely different mechanism. Furthermore, despite the requirement for PKCε-
14.3.3 complex formation in the completion of cytokinesis (Saurin et al., 2008), 14.3.3 
binding to the phosphorylated S346 and S368 residues (or indeed their phosphorylation 
per se) does not mediate PKCε-M486A recruitment to the furrow/midbody either 
(Figure 4.3). In contrast, I have shown that the IC1D, encompassing a previously 
identified actin-binding motif (Prekeris et al., 1996), is required for the accumulation of 
PKCε-M486A at the furrow/midbody upon NaPP1 stimulation (Figure 4.4). Given that 
the only difference between this and full length construct is the presence or absence of 
the IC1D this data demonstrates that the IC1D in PKCε-M486A is needed for 
recruitment whilst also confirming the specificity of the NaPP1. Crucially, PKCε-
ΔIC1D-M486A  appeared to remain correctly folded, primed and catalytically active, as 
demonstrated by Figures 4.5, 4.6 and 4.7. It therefore, seems unlikely that the lack of 
accumulation at this compartment is a consequence of the non-functional folding of 
PKCε-ΔIC1D-M486A, rather it reflects a specific involvement of the IC1D in the 
furrow/midbody recruitment process. Interestingly, whilst not influencing the C1 
domain recruitment through phorbol esters, this domain is also required for the initial 
membrane association when selectively inhibited with NaPP1 (Figure 4.4). Based on 
the data from Chapter 3, this suggests that yet other specific contacts are made and/or 
distinct regulatory inputs operate at the midbody. Although 14.3.3 was shown not to 
mediate the absolute PKCε-M486A furrow/midbody recruitment, perhaps it more subtly 
affects the dynamics once localized there. The dynamics of PKCε-S346,368A-M486A 
association at the midbody could be assessed by FRAP analysis. 
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It has not been possible to determine whether the IC1D is unequivocally required for the 
physical association of PKCε-M486A and actin. Cosedimentation assays were 
performed to compare the ability of PKCε-ΔIC1D-M486A to bind F-actin with that of 
PKCε-M486A (Figure 4.8).  While the evidence indicates that on activation with PMA, 
PKCε-ΔM486A interacts better with F-actin than that of PKCε-ΔIC1D-M486A, the 
ability of recombinant PKCε to sediment in the absence of polymerized actin, indicates 
that some portion of epsilon is insoluble or aggregates during the assay despite attempts 
to preclear this lysate. Consequently it is very difficult to interpret this assay 
unequivocally. Indeed, these assays were tested under a variety of conditions with fresh 
or precleared PKCε, however, the consistency of behaviour was lacking not enabling a 
clear conclusion to be drawn at all. An alternate strategy would be to assess whether a 
linear binding epitope of IC1D can bind actin using a peptide array. It is of note, 
however, that the linearization of both the IC1D and actin in this approach may prove 
problematic.  
Nonetheless, in this chapter I have demonstrated that the IC1D functions in part to 
recruit PKCε -M486A to the plasma membrane and furrow/midbody. Although 
previously identified as an actin-binding motif formal confirmation of this direct 
interaction has not been accomplished. An attempt to assess the relationship between 
actin and PKCε-M486A furrow/midbody recruitment is described in Chapter 5.  
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Chapter 5.  
 
F-actin regulation of a PKCε-RhoA compartment during cytokinesis 
 
5.1 Summary 
 
To assess the relationship between actin and PKCε-M486A recruitment I have 
manipulated actin polymerization. Using latrunculin A (latA), an inhibitor of F-actin 
assembly, I have shown that PKCε-M486A and RhoA colocalize and are stabilized in 
the same compartment in conditions where F-actin is destabilized independently of 
PKCε-M486A inhibition (in contrast to PKCε-M486A and NaPP1, see chapter 3). This 
condition may be analogous to a stage in midbody biogenesis and may be evidence of 
the requirement of F-actin for normal PKCε and RhoA kinetics. The equatorial 
accumulation of PKCε-M486A-RhoA in this assay is short lived and its disappearance 
correlates with the appearance of residual actin-rich structures, possibly reflecting a 
complex relationship between RhoA and actin during cytokinesis. Interestingly, 
treatment with NaPP1 prolongs the association of PKCε-M486A with this undefined 
structure, which may reflect PKCε’s actin binding/turnover capability and subsequent 
retention at the structure if in an inhibited state.  
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5.2 Introduction  
 
Actin is one of the most highly conserved and abundant proteins in eukaryotic cells and 
many cellular processes (including cell motility, endocytosis and cytokinesis) are 
powered by its rapid polymerization (recently reviewed in Campellone, 2010, Firat-
Karalar and Welch, 2011). In cytokinesis, F-actin is a major constituent of the 
actomyosin ring and assembles downstream of RhoA activation (Glotzer, 2005). 
Specifically, RhoA is activated in anaphase by Ect2 (Kimura et al., 2000) and then 
functions at the cleavage furrow to directly activate the actin-nucleating protein mDia2 
and promote the phosphorylation of the regulatory light chain of myosin II (Amano et 
al., 1996, Madaule et al., 1998, Yuce et al., 2005). Once the filaments are assembled, 
the progressive sliding of myosin minifilaments along actin filaments is then believed to 
provide the contractile force necessary to drive furrow ingression. The RhoA activated 
furrow continues to ingress until the dividing cells remain connected by an intracellular 
bridge containing a midbody. Completion finally occurs when the bridge is resolved to 
create two daughter cells.  
It has been proposed that the removal of actin is a necessary prerequisite for this final 
stage of abscission and could be controlled by the inactivation of RhoA. Given that 
PKCε-M486A accumulates at the furrow/midbody on exposure to NaPP1 and is 
associated with an enrichment of RhoA-GTP and polymerized actin (Saurin et al., 
2008), it is anticipated that PKCε triggers RhoA inactivation during cytokinesis. 
Interestingly, evidence from chapter 4 indicates that the IC1D, which has been shown 
previously to bind actin, is required for PKCε-M486A plasma membrane and 
furrow/midbody recruitment.  
To address the relationship between PKCε-M486A and actin, I have used the actin 
depolymerizer latrunculin A, latA. LatA functions by sequestering monomeric actin and 
as a consequence filamentous actin structures fall apart (Gerisch et al., 2004). Through 
the use of live imaging techniques, to capture different stages of the cytokinetic process 
with a high temporal and spatial resolution, I have uncovered an actin-PKCε-M486A-
RhoA linked compartment. Consistent with a requirement for PKCε in RhoA 
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regulation, a PKCε-M486A-RhoA positive structure stabilizes temporarily in response 
to latA and importantly is observed without PKCε’s inhibition.  The local reappearance 
of actin is then associated with the breakdown of PKCε-M486A-RhoA which might 
suggest a PKCε-M486A-actin requirement for RhoA inactivation. 
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5.3 Results 
 
5.3.1 Equatorial accumulation of PKCε-M486A, post anaphase onset, in 
response to depolymerized actin 
 
To assess the relationship between actin and PKCε-M486A recruitment I have 
manipulated actin polymerization with latA. Initially I titrated latA to determine the 
optimum concentration of the drug to use. Treatment of the M486A cell line with 100 
nM latA caused the immediate collapse of any ingressing furrows without significant 
blebbing, as observed with higher concentrations of the drug i.e. > 200 nM. Following a 
5-10 minute incubation with latA at 100 nM PKCε-M486A appeared, equatorially 
positioned, in all cells which had undergone anaphase onset, defined here by the 
separation of chromosomes (Figure 5.1, Video 14). By contrast interphase cells did not 
show a PKC accumulation in any such structures. As demonstrated in the cell denoted 
by a white star (Figure 5.1, panel 1), accumulation of PKCε-M486A does not require 
visible furrow formation, latA was added whilst the cell was in metaphase and no 
visible furrow forms but a distinctive PKCε-M486A is clearly visible (2nd arrow). 
Initially PKCε-M486A appears to be endomembrane in nature (panel 3, red arrow) and 
becomes progressively compact over time. What resembles filamentous protrusions and 
retractions from within the structure towards the chromatin are also observed during the 
time course (panel 5, red arrow) albeit irregular and short lived. The accumulated GFP- 
PKCε-M486A persists for up to 20 minutes after which it disappears and becomes 
indistinguishable from cytoplasmic GFP-PKCε-M486A.  Interestingly, treatment with 
jasplakinolide, another actin modifying agent, did not show PKC accumulation in any 
such structures in either interphase or mitotic cells (Figure 5.2) for anyconcentration 
tested (25-1000 nM).  In contrast to latA, jasplakinolide is an actin polymerising and 
filament stabilising drug (Bubb et al., 1994).   
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Figure 5-1 Depolymerization of actin with latA causes an equatorial accumulation 
of PKCε-M486A during anaphase/telophase  
Still images, taken from a time-lapse video, of the M486A cell line in the presence of 
latA (100 nM). The white star in panel 1 (top left) is indicative of the cell in metaphase. 
The arrowhead in panel 3 (top right) indicates the vesicular nature of the initial 
equatorial GFP-PKCε-M486A positive structure whereas the arrowhead in panel 5 
(middle bottom) indicates the protrusion of the structure towards DNA. The absence of 
the GFP-PKCε-M486A positive structure in panel 6 (10 minutes later) highlights its 
dynamic nature.  
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Figure 5-2 Deplolymerization of actin with jasplakinolide does not result in an 
equatorial accumulation of PKCε-M486A during anaphase/telophase  
Still images, taken from a time-lapse video, of the M486A cell line in the presence of 
jasplakinolide (500 nM).  
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5.3.2 Equatorial accumulation of PKCε-M486A does not colocalize with 
lagging chromosomes 
 
To assess whether the latA induced PKCε-M486A positive structure is positioned 
adjacent to or has any close association with DNA I have used the M486A cell line 
stably expressing mCherry-Histone 2B (H2B). In a representative dividing PKCε-
M486A-H2B expressing cell (Figure 5.3), latA addition as expected leads to a 
reasonably equatorial, transient GFP-PKCε−Μ486Α positive structure. This behaviour 
is similar to that observed in the PKCε-M486A only expressing cells. PKCε-M486A 
does not colocalize with the bulk of DNA nor is it localized adjacent to it. It is of 
particular note, however, that this doesn’t exclude the possibility of an interaction with 
fine chromatin bridges. Indeed there is an indication of possible interactions between 
this structure and DNA, as evidenced by a transient protrusion towards condensed 
chromosomes on one side of the dividing cell (panel 4). In the absence of latA, PKCε-
M486A-H2B expressing cells complete cytokinesis normally with no change in the 
distribution of PKCε-M486A.  
 
5.3.3 The dynamic nature of PKCε-M486A is linked to the state of actin 
polymerization  
 
In order to determine when actin depolymerization influences PKCε-M486A 
accumulation I monitored the appearance and localization of MARS-lifeact-RFP (Riedl 
et al., 2008) coexpressed in the PKCε-M486A cell line (Figure 5.4). Prior to the 
addition of drug, in a dividing cell, actin is distinctly cortical and as expected 
accumulates at the ingressing furrow (Figure 5.4, panel 1, Video 16). Following 
treatment with latA, the furrow regresses accompanied by a simultaneous loss of 
polymerized actin (Figure 5.4 panel 2). The behaviour of PKCε-M486A is then similar 
to that observed in the PKCε-M486A only expressing cells and its accumulation is not 
associated with any detectable  
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Figure 5-3 The latA induced PKCε-M486A positive structure does not colocalize 
with lagging chromosomes  
Still images, taken from a time-lapse video, of the M486A cell line stably expressing 
H2B. The accumulation of GFP-PKCε-M486A is spatially distinct from that of DNA.  
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   LatA addition   
       1                      2                         3                      4                     5                      6 
 
B 
 
Figure 5-4 The dynamic behaviour of the latA induced PKCε-M486A positive 
structure is linked to actin depolymerization and the reappearance of residual 
actin rich structures 
Still images, taken from a time-lapse video, of the M486A cell line transiently 
expressing MARS-lifeact-RFP. A) Arrowheads in panel 1 (far left, second row) indicate 
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Figure 5.4 continued relative cortical actin accumulation and preferential furrow 
accumulation in actively dividing cells prior to treatment with latA. Panel 2 shows the 
loss of MARS-lifeact upon latA exposure whilst arrowheads in panel 3 (top row) are 
indicative of the equatorial GFP-PKCε-M486A accumulation. The GFP-PKCε-M486A 
positive structure persists for approximately 15 minutes and disappearance correlates 
with the robust reappearance of MARS-lifeact, as shown in panels 5 and 6.  B) In the 
absence of latA, cells complete furrowing normally with no change in the distribution of 
GFP-PKCε-M486A. Actin accumulates as expected at the furrow and midbody, where 
it persists for approximately 40 minutes until its disassembly coincides with abscission. 
In panel 4, the contrast has been modified to take into account unpreventable bleaching.   
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levels of MARS-lifeact-RFP (panel 3). Surprisingly, the local reappearance of MARS-
lifeact-RFP briefly overlaps with the PKCε-M486A positive structure (panel 4) until the 
GFP-PKCε-M486A breaks down (panels 5 and 6). This suggests that actin 
polymerization is linked directly to the control of a PKCε-M486A positive structure 
and/or PKCε retention to a structure. 
 
5.3.4 The PKCε-M486A positive structure is more pronounced and long-
lived upon the addition of NaPP1 
 
As previously mentioned, the latA induced PKCε-M486A positive structure persists for 
up to 20 minutes, all attempts to biochemically fix the structure failed, which suggest 
that either the structure itself is impenetrable to antibody or it’s simply a reflection of its 
fragility. Surprisingly, upon the addition of NaPP1 and consequent PKCε-M486A 
inhibition, the latA-induced PKCε-M486A positive structure is much more pronounced 
and long-lived, with life-times ranging from 40-60 minutes (Figure 5.5, Video 15). This 
may reflect its retention on the re-localized actin whilst in an inactive state. The inactive 
PKCε-M486A positive structure is now amenable to fixing (Figure 5.6, 5.7).  
 
5.3.5 RhoA colocalizes with the PKCε-M486A positive structure whilst 
key RhoA regulators do not 
 
Although the polymerization state of actin appears intricately linked to the dynamics of 
PKCε-M486A, it does not resolve the molecular composition of its associated structure. 
To probe for potential candidates, M486A cells in the presence of latA and NaPP1 have 
been fixed. This has provided evidence for the co-localization of RhoA with PKCε-
M486A (Figure 5.6) but not other cell cycle proteins associated with cytokinesis (Figure 
5.7) and potentially influencing RhoA function, including Ect2 and MKLP1.                  
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Figure 5-5 The latA induced PKCε-M486A positive structure is much more 
pronounced and long-lived when treated with NaPP1  
Still images, taken from a time-lapse video, of the M486A cell line pre-treated with latA 
(100 nM for 5-10 minutes- or until first visual of GFP-PKCε positive structure) and 
then NaPP1 (4 µM). The panels are indicative of the progression of a PKCε-M486A 
positive structure under both these conditions.  
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Figure 5-6 A latA and NaPP1 induced PKCε-M486A positive structure colocalizes 
with RhoA  
For the fixed images in the first three rows, GFP-PKCε-M486A cells were treated with 
either a DMSO control, NaPP1 (4 µM) or latA (100 nM) for 10 minutes. In the final 
row of images, cells were pre-treated with latA for 10 minutes followed by a further 10 
minute treatment with NaPP1. Cells were fixed and stained for PKCε (red), RhoA 
(blue) and DAPI (pink). PKCε and RhoA colocalize following either NaPP1 treatment 
or a combination of latA and NaPP1 treatment. For the fixed images in panel row 3, no 
PKCε positive structure is observed with latA treatment only.  
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Figure 5-7 A latA and NaPP1 induced PKCε-M486A positive structure does not 
colocalize with other proteins associated with cytokinesis   
GFP-PKCε-M486A cells were pre-treated with latA (100 nM) for 10 minutes followed 
by treatment with NaPP1 (4 µM) for a further 10 minutes. Cells were fixed and stained 
for a variety of cytokinetic associated proteins as indicated in the Figure (blue), PKCε 
(green) and DAPI (pink).  
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It is of note that two different methods of fixing were employed (see materials and 
methods). 
 
5.3.6 A dynamic PKCε-M486A-RhoA structure in response to latA 
 
In order to confirm the latA induced colocalization of RhoA with PKCε-M486A, I 
monitored the appearance and localization of cherry-RhoA coexpressed in the M486A 
cell line (Figure 5.8A, Video 17). Following treatment with latA the transient behaviour 
of PKCε-M486A is similar to that observed in the PKCε-M486A only expressing cells 
but importantly, its accumulation precisely overlaps with cherry-RhoA. In the absence 
of latA no such PKCε-M486A-RhoA positive structure accumulates and the distribution 
of the two are expected. To test for spectral bleed-through in these double-labelled cells, 
I monitored the appearance of a latA induced GFP-PKCε-M486A positive structure in a 
cell not expressing cherry-RhoA (Figure 5.8C). GFP-PKCε-M486A accumulation did 
not bleed-through to the cherry-RhoA channel.   
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LatA addition 
 
B 
 
Figure 5-8 The latA induced PKCε-M486A positive structure colocalizes with 
RhoA   
Still images, taken from a time-lapse video, of the M486A cell line transiently 
expressing cherry-RhoA. A) The accumulation and disappearance of GFP-PKCε-
M486A precisely overlaps with that of cherry-RhoA. B) In the absence of latA cells 
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Figure 5.8 continued complete furrowing normally with no PKCε-M486A-RhoA 
positive structure forming. Cherry-RhoA accumulates as expected at the 
furrow/midbody .C) The colocalization of PKCε and RhoA is not a consequence of 
GFP spectral bleed-through.  
 
C 
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5.4 Discussion 
 
Selective inhibition of PKCε-M486A causes localization of the enzyme at the 
furrow/midbody with RhoA-GTP and polymerized actin (Saurin et al., 2008). How its 
particular control is exerted here remains to be defined but it has been proposed that 
PKCε functions to reduce RhoA-GTP and permit actin depolymerization. Consistent 
with the role of PKCε in regulating this final stage of cytokinesis, I have uncovered an 
actin-PKCε-M486A-RhoA linked compartment, which importantly is observed without 
PKCε-M486A’s inhibition and may help define its behaviour here. 
Work in the previous chapter identified the IC1D as being involved in the recruitment 
of PKCε-M486A to the furrow/midbody. Although, previously identified as an actin-
binding motif (Prekeris et al., 1996), I have been unable to provide direct evidence to 
support this interaction. Rather, to assess the relationship between actin and PKCε-
M486A recruitment I have manipulated actin polymerization using latA. At the normal 
time of furrowing, the addition of latA leads to the depolymerization of actin and the 
stabilisation of an equatorial PKCε-M486A-RhoA positive structure (Figure 5.1 and 
5.8). The accumulation of PKCε-M486A and RhoA is relatively short lived, persisting 
for up to a maximum of 20 minutes and then disappearing, surprisingly, correlating with 
the re-appearance of residual actin-rich structures. Whilst it has been demonstrated that 
the reorganisation of F-actin following depolymerization with latA is possible upon the 
removal of the drug (Gerisch et al., 2004), it is intriguing that residual actin rich 
structures can form here whilst still in the presence of latA (albeit low concentrations). 
Interestingly, these actin structures specifically relocalize to the furrow, accumulating 
either adjacent to or slightly overlapping with the GFP-PKCε-M486A positive structure 
(Figure 5.4). Nevertheless, this data suggests that F-actin maybe required for PKCε 
turnover. Consistent, with this hypothesis, treatment with the actin stabilising drug 
jasplakinolide, does not induce the appearance of any such PKC positive structures 
(Figure 5.2) suggesting that the mere retention of F-actin, albeit in a non-physiological 
form, is not sufficient to suppress PKCε turnover.  Furthermore, the addition of NaPP1 
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prolongs the existence of the GFP-PKCε-M486A positive structure, perhaps reflecting a 
stronger retention of inactive PKCε-M486A on actin (Figure 5.5).  
In view of the proposed role of actin in recruiting PKCε-M486A to the furrow/midbody, 
it is intriguing that PKCε-M486A is located here apparently in the absence of actin. It 
has been suggested previously that Rab11/FIP3 endosomes, in addition to membrane 
expansion, deliver proteins that are necessary for the completion of cytokinesis. 
Specifically, the sequential binding of MgcRacGAP to Ect2 and FIP3 is thought to 
regulate actomyosin ring dissociation (Simon et al., 2008). Given the probable 
endomembrane nature of the latA-induced GFP-PKCε-M486A positive structure, it is 
plausible that accumulation of PKCε-M486A is in part a function of membrane 
trafficking, whether this reflects an alternative actin-independent pathway or whether it 
is merely indicative of an interaction with further components at the midbody in an 
actin-dependent pathway remains to be defined. Nonetheless, to test the involvement of 
Rab11 and other potential candidates involved in membrane trafficking it would be 
informative to monitor PKCε-M486A recruitment in response to latA after employing 
siRNA knock-down of Rab11 and functionally related proteins. In addition, the delivery 
of these vesicles has been reported to be mediated by microtubules. This is of interest 
because of the protrusions observed from the GFP-PKCε-M486A positive structure 
toward DNA. To test whether these reflect a dependence on the microtubule network, 
more specifically the central spindle, the microtubule destabilizer nocodazole could be 
tested.  
It seems unlikely that the latA induced GFP-PKCε-M486A positive structure described 
is a non-specific aggregate of proteins given its transient nature and the fact it can be 
stabilized by PKCε-M486A inhibition. Rather, I propose that the disruption of F-actin 
causes an active PKCε-M486A-RhoA positive structure to stabilize in a manner 
possibly analogous to a snapshot of midbody biogenesis and could therefore be useful 
in understanding how PKCε exerts its function there. PKCε may reduce RhoA-GTP 
loading by either driving a decrease in RhoGEF activity or an increase in RhoGAP 
activity. However, whilst anticipating an increase in RhoA-GTP loading in the presence 
of latA due to its phenocopy with PKCε-M486A and NaPP1, the activation status of 
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RhoA in the presence of latA remains uncharacterized. Confirmation of the activity of 
RhoA during this process is still required. If evidence is generated to indicate that latA 
maintains RhoA in an active state, there are many candidate proteins PKCε might then 
influence to inactivate RhoA, most notably Ect2 and MgcRacGAP. Recent work in our 
laboratory has uncovered 3 very high scoring candidate nPKC sites on Ect2 and 
Minoshima et al have reported a phosphorylation at S387 on MgcRacGAP which 
induces GAP activity at the late stages of cytokinesis (Minoshima et al., 2003). These 
could be tested for PKCε control and their phosphorylation monitored during latA 
treatment. Furthermore, the effect of siRNA on GEF/GAP candidates and RhoA itself 
could be investigated in conjunction with overexpression studies of GEF/GAP and their 
mutant forms. In an attempt to summarize the findings of this chapter please see Figure 
5.9.  
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Figure 5-9 A model outlining the understanding of PKCε  regulation in the absence 
and presence of latA 
(Reprinted by permission from Macmillan Publishers Ltd, Nat Rev Mol Cell Biol, 
Glotzer, The 3Ms of central spindle assembly: microtubules, motors and MAPs, 10, 9-
20, 2009). With latA. 1)Actin (orange ring) is required for PKCε (yellow arrow) 
delivery and turnover at the furrow/midbody. 2) RhoA inactivation is required for actin 
ring dissociation which may be driven by an interaction with PKCε and as yet an 
unidentified component (green). With latA. Loss of pre-formed actin ring causes the 
collapse of any ingressing furrow and prevents the turnover of PKCε such that it 
becomes ‘trapped’ on the unknown with RhoA.  
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Chapter 6. Discussion 
 
Prior to this thesis work had demonstrated that recruitment of PKCε to the 
furrow/midbody and assembly into a complex with 14.3.3 is required for the successful 
completion of cytokinesis (Saurin et al., 2008). Although the molecular mechanism of 
this control is undefined, PKCε is thought to be required for the inactivation of RhoA 
and consequent actin depolymerization associated with abscission (Saurin et al., 2008). 
Importantly, failure to complete cytokinesis can lead to genetically unstable tetraploid 
cells, a prelude to aneuploidy and tumour formation (Fujiwara et al., 2005). Precise 
mapping of cytokinesis at a molecular level is, therefore, a necessary prerequisite for 
the assessment of whether intervention in this process might bring about benefits in the 
treatment of cancer. In an attempt to derive a more specific understanding of how PKCε 
exerts its function during cytokinesis, I have addressed the mechanism by which PKCε 
is localized at the furrow/midbody. Unfortunately, the furrow/midbody has proved 
difficult to assess biochemically due to its relatively infrequent nature and the intrinsic 
difficulty in synchronizing cells in cytokinesis. To overcome this problem I have 
attempted to molecularly define aspects associated with the furrow/midbody with the 
use of extensive live confocal microscopy and mutagenesis. Indeed this has proved 
relatively successful, however, monitoring the process in single cells does prove 
challenging for vast data collections.  
As demonstration of the localization of an uninhibited PKCε at the furrow/midbody has 
remained elusive, perhaps reflecting the transient nature of the association, I have 
employed the use of a chemical genetic approach using the NaPP1 sensitive PKCε-
M486A (Bishop et al., 1998, Bishop et al., 2000, Durgan et al., 2008, Saurin et al., 
2008). Although this system relies on ectopic expression of mutant forms of PKCε and 
non-physiological stimuli, it has provided key mechanistic insight concerning the 
involvement of PKCε in cytokinesis. Furthermore, the validity of this approach is 
evidenced by the finding that NaPP1 addition to induced WT cells has no effect (Figure 
3.3) and treatment with a c/nPKC inhibitor, Bim1, shows a similar PKCε midbody 
localization (Figure 3.5). Although the PKCε-M486A, when compared with PKCε-WT, 
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demonstrates a reduced affinity for ATP, which is reflected in the instability of priming 
phosphorylations (Cameron et al., 2009), this loss is acceptable and indeed proved 
useful when characterising the PKCε-ΔIC1D-M486A deletion mutant (Figure 4.6).  
Demonstration of an interaction of endogenous kinase at the furrow/midbody would be 
preferable but as already mentioned, the transient nature of this association is currently 
not amenable to probing with the approaches available. However, the PKCε-M486A-
RhoA positive structure that appears independently of PKCε-M486A inhibition during 
cytokinesis (Chapter 5, Figure 5.1) may shed light on PKCε behaviour here.  
 
6.1 PKCε-M486A furrow/midbody recruitment and retention 
 
PKCε-M486A localizes to the plasma membrane before becoming concentrated at the 
furrow/midbody when selectively inhibited with NaPP1 (Chapter 3, Figure 3.2). Using 
mutation and deletion analysis I have shown that localization at both compartments is in 
part a function of the IC1D (Figure 4.4), a motif previously identified as actin binding 
(Chapter 4, Prekeris et al., 1996, Prekeris et al., 1998). If evidence is generated to 
confirm that the IC1D is an actin-binding motif, then the working hypothesis becomes 
such that whilst in its active state PKCε-M486A retention on actin (cortical and 
contractile ring) is poor in response to normal physiological stimuli; it is implicit that 
catalytic activity is required for its release from actin, regardless of the stage of the cell 
cycle.  
Given that at the early stages of furrow formation PKCε-M486A is associated with non-
juxtaposed plasma membranes, I propose that the IC1D functions in a similar manner to 
recruit PKCε-M486A to both the plasma membrane and early furrow. It seems likely 
that the initial plasma membrane recruitment of PKCε serves as a prelude to that at the 
furrow by bringing about a conformational change, however it is also plausible that 
PKCε is involved in monitoring the site of cell division, in a concentration dependent 
manner. Perhaps the inhibition of PKCε at this early stage in then only evident at the 
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point of RhoA inactivation. Or perhaps, PKCε could have dual functionality and once 
reaching a threshold at the midbody change function and acts on abscission. To test the 
involvement of PKCε in furrow formation it might informative to monitor PKCε 
knockdown cells and measure the distance between the centralspindlin complex and the 
actomyosin ring to see if there are any changes.  
Nevertheless, the distinct and concentrated localization of the enzyme at the 
invaginating furrow/midbody may reflect further interactions of the open conformer 
with other specific contacts These additional contacts at the furrow/midbody, however, 
do not appear to be related to those at cell-cell contacts. In Chapter 3 (Figure 3.6), I 
demonstrated, using FRAP, that PKCε-M486A has a significantly slower turnover at 
the furrow/midbody compared with the dynamics at cell-cell contacts, which is 
indicative of a distinct, more complex retention mechanism at the furrow/midbody. 
When probing other potential candidates involved in PKCε-M486A retention at the 
furrow/midbody FRAP analysis may prove invaluable. For example, despite the finding 
that 14.3.3 is not required for PKCε-M486A recruitment to the furrow/midbody (Figure 
4.3) it is plausible that 14.3.3 may act to subtly alter PKCε dynamics once localized 
there. Given that Saurin and colleagues proposed that 14.3.3 binding serves to act as a 
‘conformational clamp’ locking PKCε into an active open conformation, a consequence 
of such stabilization could increase its retention at the furrow/midbody; it might be 
useful to compare the dynamics of PKCε-M486A and PKCε-S346,368A-M486A. 
An alternative explanation for the source of additional contacts at the midbody may 
come from the latA experiments (Chapter 5). It is intriguing that PKCε-M486A is 
localized to a structure reminiscent of the midbody, without prior accumulation at the 
furrow, when cells are treated with latA (Figure 5.1, 5.5, 5.7). As suggested in the 
chapter, the endomembrane nature of the latA-induced structure may reflect a 
dependence on the membrane trafficking network. Two distinct populations of vesicles 
have been associated with the completion of cytokinesis, Rab6 golgi-derived vesicles 
and Rab11 vesicles derived from recycling endosomes (Simon et al., 2008, Hill et al., 
2000).  It is of particular interest that Rab11 localization to the midbody depends on 
binding FIP3. The latter has itself been implicated in regulating Ect2 dissociation at the 
centralspindlin by binding to MgcRacGAP and consequently reducing RhoA-GTP 
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(Simon et al., 2008). It is plausible, therefore, that PKCε-M486A may exert its function 
on RhoA via this pathway. It might be informative to monitor the effect of PKCε-
M486A in response to latA and NaPP1 after siRNA knockdown of Rab11, Rab6 and 
other potential trafficking candidates. Regardless of whether evidence is generated to 
support the requirement of membrane trafficking for PKCε-M486A localization at the 
midbody, the microtubule network should also be investigated. In addition to it 
facilitating membrane trafficking, it is also plausible that microtubules function at this 
stage as a platform for key cytokinetic regulators that could include PKCε. To assess the 
involvement of the microtubule network it would be possible to treat the cells with the 
microtubule destabilizer, nocodazole and monitor the PKCε-M486A response. 
However, given that nocodazole treatment might act to disrupt the midbody and its 
associated proteins, perhaps a less destructive approach would be to target the motor 
proteins that power transport along microtubules instead, such as a small screen using a 
library of kinesin inhibitors or siRNA.   
In addition to the IC1D, it was hypothesized that DAG formation, via Ca2+ dependent-
PLC hydrolysis of PIP2, functions to regulate PKCε-M486A recruitment to the plasma 
membrane and furrow/midbody.  Interestingly, the local production of PIP2 at the 
furrow is required for the successful completion of cytokinesis (Saul et al., 2004, Wong 
et al., 2005) and may reflect the downstream, albeit short-lived, DAG production at this 
compartment. An attempt in Chapter 3 was made to assess the contribution of DAG in 
PKCε-M486A localization. Surprisingly, rather than having a negative effect, Ca2+ 
depletion led to the retention of PKCε-M486A at the plasma membrane in suspended 
cells (Figure 3.7, 3.8) however, in contrast FRAP analysis failed to demonstrate any 
significant change in the kinetics of PKCε-M486A at either cell-cell contacts or the 
furrow/midbody (Figure 3.10), the discrepancy between these two results may reflect 
the unique suspension behaviour of these cells and/or the nature of the cell-cell contacts 
in the two environments. These results are preliminary and the destruction of DAG may 
be incomplete in this experiment and off-target effects may occur due to the non-
specific nature of this experiment. Perhaps a more conclusive approach would be the 
employment of siRNA directed specifically at PLCs and/or mutations within the C1 
domain of PKCε-M486A preventing DAG binding. Given that DAG binds to the 
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tandem C1A and C1B domains I would propose to convert critical prolines to glycines 
at sites 180 in C1A and 253 in C1B (Hurley et al., 1997, Bogi et al., 1998).  
Collectively, the results of these studies show a requirement for the IC1D in both 
plasma membrane and furrow/midbody localization.  The reason for the altered 
association of PKCε-M486A at the furrow/midbody is not yet clearly resolved. 
However, I have shown through FRAP experiments that the process may be different to 
PKCε-M486A accumulation at cell-cell contacts. I have identified other potential 
candidates that could be involved and have proposed the necessary follow-up 
experiments. It is hoped that these will define the distinct behaviour of PKCε-M486A at 
the furrow/midbody. For a revised model of PKCε regulation and localization see 
Figure 6.1. 
 
6.2 PKCε-M486A and actin, consequences for RhoA control 
 
Work throughout this thesis has attempted to characterize PKCε-M486A recruitment to 
the furrow/midbody. Although refinement of this pathway is required, actin has been 
implicated as a key regulator. Actin not only functions during cytokinesis to drive the 
constriction of the invaginating furrow but may also serve as a platform to recruit and 
maintain the constant turnover of PKCε-M486A, as described in my working 
hypothesis. Furthermore, as identified in Chapter 5, it also appears to be intimately 
linked to PKCε-M486A control of RhoA (Figure 5.5, 5.7). Manipulation of actin 
polymerization (latA) at the normal time of furrowing leads to an equatorial PKCε-
M486A-RhoA compartment temporarily forming, independently of PKCε-M486A 
inhibition (Figure 5.1). Consistent with my working hypothesis, the local reappearance 
of actin, then triggers the release of active PKCε-M486A along with RhoA from this 
undefined structure (5.3, 5.7).   
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Figure 6-1 Updated schematic summarizing how PKCε  localization is controlled 
(Reprinted and adapted with permission from Macmillan Publishers Ltd: Nature Cell 
Biology, Saurin et al, 10, 891-901, 2008). 1) The GEE motif selectively targets PKCε to 
cell-cell contacts (as in previous model) but is not required for furrow/midbody 
recruitment. 2) Membrane and furrow/midbody recruitment is mediated through the 
IC1D which is thought to be actin (pink) binding. As to whether membrane binding is a 
prerequisite for furrow/midbody binding remains unknown. As does the precise timing 
of phosphorylation by PKC, p38 and GSK3 but importantly PKCε-14.3.3 complex 
assembly is not required for PKCε localization at the furrow/midbody (3). Once at the 
furrow/midbody, 14.3.3 is then believed to maintain PKCε in an active, open 
conformation where it is thought to control RhoA-GTP loading.  
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In principle, treatment with latA could effectively ‘stabilize/trap’ PKCε-M486A at 
components with which it additionally associates once at the midbody. Interestingly 
active PKCε-M486A colocalizes at this structure with RhoA (Figure 5.5, 5.7), similar to 
the midbody localization of PKCε-M486A and RhoA in response to NaPP1 (Saurin et 
al., 2008). Given that treatment with NaPP1 is also associated with an increase in 
RhoA-GTP (Saurin et al 2008) due to this phenocopy it is expected that RhoA  may be 
in its GTP bound form during latA treatment. However, this is purely speculative, it is 
possible that the depolymerization of actin, may function to mimic the terminal stage of 
cytokinesis, by-passing the need for active RhoA and instead trigger its inactivation. 
Therefore, monitoring the activity of RhoA during latA treatment is now required to 
clarify the nature of this compartment.  
With regards to PKCε’s function in this undefined structure, like that at the midbody in 
response to NaPP1, it is expected to control RhoA via either decreasing the activity of a 
GEF or increasing activity of a GAP. There are many candidate proteins that PKCε 
might influence including Ect2 and MgcRacGAP. A generic approach to identify PKCε 
targets should be tractable through a combination of NaPP1 and latA treatment using 
immuno-fluorescence. Although preliminary evidence indicates that MKLP1, a marker 
of the centralspindlin and Ect2 do not colocalize with this structure (Figure 5.6) their 
phosphorylation status remains unknown and MgcRacGAP has not been tested. Given 
the transient nature of this structure and the difficulty in fixing, a complementary and 
arguably more conclusive approach would be to also employ a single-cell readout 
approach using RFP constructs of potential candidates coexpressed with GFP-PKCε-
M486A in live imaging.  
Nevertheless, the observation that PKCε-M486A can accumulate with RhoA in its 
active state is important and may shed light on PKCε behaviour in cytokinesis. Indeed 
this condition may be analogous to a stage in midbody biogenesis and may be evidence 
of the requirement for F-actin for normal PKCε-M484A and RhoA turnover.  I therefore 
propose that work should continue to address the additional components of this 
undefined structure. This would also include probing the aforementioned vesicle 
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trafficking system and deducing the activity/phosphorylation states of those components 
successfully identified.  
 
6.3 PKCε-M486A and Ca2+  
 
In view of the classification of PKCε as a Ca2+ independent PKC, it is surprising to 
observe that PKCε-M486A displays Ca2+ sensitivity in terms of its cell-cell contact 
recruitment (Figure 3.7, 3.8). In suspension, I have shown that Ca2+ depletion leads to 
an increase in retention of inactive PKCε-M486A at cell-cell contacts and cells prove 
considerably harder to separate (Figure 3.9), both indicative of a change in the affinity 
or avidity of the interactions found here. Consistent with this response, in culture, 
disruption to cell-cell contacts and extensive shrinkage induced by EGTA was 
completely blocked by pre-treatment with NaPP1 (Figure 3.11).  Interestingly, this 
PKCε protection is only apparent if the cells are plated on poly-L-lysine coated cover 
slips and their integrins are not engaged. As such, this may reflect a unique pathway in 
operation when for example cancer cells are undergoing metastatic spread and 
consequently this phenomenon deserves further investigation. 
Given the increasing amount of evidence which shows that Ca2+ can directly regulate 
protein-protein interactions, I propose that Ca2+ directly regulates a PKCε-M486A-
protein interacting protein specifically at cell-cell contacts. A candidate interacting 
protein would be the scaffold protein ENH. Ca2+ regulates the association of PKCε-
ENH and consequently the formation of a PKCε-ENH-N_type Ca2+ channel complex in 
neuronal cells (Chen et al., 2006). Whether this scaffolding protein plays a role in 
conferring Ca2+ sensitivity of PKCε-M486A in HEK293 cells remains to be determined 
but could be assessed by employing siRNA against ENH. 
One other notable family of potential PKCε interacting proteins are the cadherins. 
Interestingly, they are linked to actin through catenins and a variety of studies have 
shown that they are internalized by Ca2+ depletion (Alexander et al., 1993, Alexander et 
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al., 1998, Le et al., 1999, Kamei et al., 1999). In view of the proposed role of the IC1D 
in binding actin it is plausible that inhibited PKCε-M486A accumulates at actin and 
consequently prevents the internalization of cadherins when exposed to EGTA. 
Consistent with this hypothesis, pre-treatment with staurosporine, an ATP-competitive 
kinase inhibitor, has been shown to block low Ca2+ mediated cell rounding and cadherin 
endocytosis (Alexander et al., 1998). To determine whether cadherins play a role in 
conferring PKCε-M486A Ca2+ sensitivity in HEK 293 cells it would be useful to 
employ siRNA and monitor PKCε-M486A response in both suspended and cultured 
cells. Furthermore, to assess the internalization of cadherins one could employ a trypsin 
protection assay whereby surface vs. internalized cadherins can be measured and their 
reappearance monitored after calcium restoration.   
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Final comments 
To derive a more specific understanding of PKCε function in cytokinesis I have 
addressed the mechanism by which PKCε-M486A is localized to the furrow/midbody. 
The data presented throughout this thesis suggests that actin is a key regulator required 
for PKCε-M486A accumulation at the furrow/midbody and once at the midbody maybe 
required for PKCε-RhoA turnover. 
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Appendix 
 
Supplementary Videos 
 
Chapter 3 
 
Video 1: PKCε-M486A expressing cells undergoing normal mitosis 
Video 2: Selective inhibition of PKCε-M486A, showing accumulation 
at the furrow/midbody  
Video 3: EGTA addition to PKCε-M486A expressing cells (plated on 
poly-L-lysine) causes significant cell shrinkage and disruption to cell-
cell contacts 
Video 4: NaPP1 addition to PKCε-M486A expressing cells (plated 
on poly-L-lysine) protects cells from the effects of EGTA 
Video 5: EGTA addition to PKCε-WT expressing cells (plated on 
poly-L-lysine) causes cell shrinkage and disruption to cell-cell 
contacts 
Video 6: NaPP1 addition to PKCε-WT expressing cells (plated on 
poly-L-lysine) does not protect cells from the effects of EGTA 
Video 7: EGTA addition to PKCε-M486A expressing cells (plated on 
fibronectin) causes significant cell shrinkage and disruption to cell-
cell contacts 
Video 8: NaPP1 addition to PKCε-M486A expressing cells (plated 
on fibronectin) does not protect cells from the effects of EGTA 
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Video 9: EGTA addition to PKCε-M486A expressing cells (plated on 
collagen) causes significant cell shrinkage and disruption to cell-cell 
contacts 
Video 10: NaPP1 addition to PKCε-M486A expressing cells (plated 
on collagen) does not protect cells from the effects of EGTA 
Video 11: EGTA addition to PKCε-M486A expressing cells (plated 
on laminin) causes significant cell shrinkage and disruption to cell-
cell contacts 
Video 12: NaPP1 addition to PKCε-M486A expressing cells (plated 
on laminin) does not protect cells from the effects of EGTA 
 
Chapter 4 
 
Video 13: Selective inhibition of PKCε-ΔIC1D-M486A does not result 
in GFP-PKCε-ΔIC1D-M486A accumulation at the furrow/midbody 
despite accumulation of the coexpressed RFP-PKCε-M486A 
 
 
Chapter 5 
 
Video 14: LatA addition to PKCε-M486A expressing cells results in 
the appearance of a transient GFP-PKCε-M486A positive structure 
in mitotic cells only (duration of positive structure = 20minutes) 
Video 15: Selective inhibition of PKCε-M486A prolongs the 
appearance and intensity of the latA induced GFP-PKCε-M486A 
positive structure (duration of positive structure = 1 hour) 
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Video 16: The transient nature of the latA induced GFP-PKCε-
M486A positive structure is linked to the polymerization state of 
actin 
Video 17: LatA induced GFP-PKCε-M486A colocalizes with RhoA at 
the undefined equatorial structure  
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Independent confirmation of FRAP analysis using 
Microsoft Excel  
 
1) Export raw data into Microsoft Excel (cells A2-D291) 
2) Background subtraction (cells G2-I291)   
3) Normalisation and corrections for fluorescence loss during photobleaching (cells 
L2-O291) 
4) Plot final fluorescence (cells R2-R291) against time, using a biexponential 
model, in Prism.  
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